WO2020212350A1 - Substituted cyanopyrrolidines with activity as usp30 inhibitors - Google Patents

Substituted cyanopyrrolidines with activity as usp30 inhibitors Download PDF

Info

Publication number
WO2020212350A1
WO2020212350A1 PCT/EP2020/060467 EP2020060467W WO2020212350A1 WO 2020212350 A1 WO2020212350 A1 WO 2020212350A1 EP 2020060467 W EP2020060467 W EP 2020060467W WO 2020212350 A1 WO2020212350 A1 WO 2020212350A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compound
fibrosis
mmol
deficiency
Prior art date
Application number
PCT/EP2020/060467
Other languages
French (fr)
Inventor
Paul William Thompson
Christopher Andrew Luckhurst
Mark Ian Kemp
Alison Jones
Original Assignee
Mission Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mission Therapeutics Limited filed Critical Mission Therapeutics Limited
Publication of WO2020212350A1 publication Critical patent/WO2020212350A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme ubiquitin C-terminal hydrolase 30, also known as ubiquitin specific peptidase 30 (USP30), uses thereof, processes for the preparation thereof and composition containing said inhibitors.
  • ubiquitin C-terminal hydrolase 30 also known as ubiquitin specific peptidase 30 (USP30)
  • USP30 ubiquitin specific peptidase 30
  • Ubiquitin is a small protein consisting of 76 amino acids that is important for the regulation of protein function in the cell. Ubiquitylation and deubiquitylation are enzymatically mediated processes by which ubiquitin is covalently bound or cleaved from a target protein by deubiquitylating enzymes (DUBs), of which there are approximately 100 DUBs in human cells, divided into sub-families based on sequence homology.
  • DUBs deubiquitylating enzymes
  • the USP family are characterised by their common Cys and His boxes which contain Cys and His residues critical for their DUB activities.
  • the ubiquitylation and deubiquitylation processes have been implicated in the regulation of many cellular functions including cell cycle progression, apoptosis, modification of cell surface receptors, regulation of DNA transcription and DNA repair.
  • the ubiquitin system has been implicated in the pathogenesis of numerous disease states including inflammation, viral infection, metabolic dysfunction, CNS disorders, and oncogenesis.
  • Ubiquitin is a master regulator of mitochondrial dynamics. Mitochondria are dynamic organelles whose biogenesis, fusion and fission events are regulated by the post-translational regulation via ubiquitylation of many key factors such as mitofusins. In humans, USP30 is a 517 amino acid protein which is found in the mitochondrial outer membrane (Nakamura et al, 2008, Mol Biol 19:1903-11). It is the sole deubiquitylating enzyme bearing a mitochondrial addressing signal and has been shown to deubiquitylate a number of mitochondrial proteins.
  • USP30 A small proportion of USP30 has been localized to peroxisomes, which are generated through fusion of mitochondrial and ER vesicles, with USP30 potentially antagonizing the Pex2/pexophagy pathway (Riccio et al, 2019, J Cell Biol 218(3): 798-807).
  • the E3 Ub ligase March5 and the deubiquitinase USP30 associate with the translocase and regulate mitochondrial import, and while March5 opposes mitochondrial import and directs degradation of substrates, USP30 deubiquitinates substrates to promote their import (Phu et al, 2020, Molecular Cell 77, 1107-1123).
  • Mitochondrial dysfunction can be defined as diminished mitochondrial content (mitophagy or mitochondrial biogenesis), as a decrease in mitochondrial activity and oxidative phosphorylation, but also as modulation of reactive oxygen species (ROS) generation. Hence a role for mitochondrial dysfunctions in a very large number of aging processes and pathologies.
  • ROS reactive oxygen species
  • Parkinson’s disease affects around 10 million people worldwide (Parkinson’s Disease Foundation) and is characterised by the loss of dopaminergic neurons in the substantia nigra.
  • the exact mechanisms underlying PD are unclear; however mitochondrial dysfunction is increasingly appreciated as a key determinant of dopaminergic neuronal susceptibility in PD and is a feature of both familial and sporadic disease, as well as in toxin-induced Parkinsonism.
  • Parkin is one of a number of proteins that have been implicated with early onset PD. While most PD cases are linked to defects in alpha-synuclein, 10% of Parkinson’s cases are linked to specific genetic defects, one of which is in the ubiquitin E3 ligase parkin.
  • USP30 has been reported that depletion of USP30 enhances mitophagic clearance of mitochondria and also enhances parkin-induced cell death. USP30 has also been shown to regulate BAX/BAK-dependent apoptosis independently of parkin overexpression. Depletion of USP30 sensitises cancer cells to BH- 3 mimetics such as ABT-737, without the need for parkin overexpression. Thus, an anti-apoptotic role has been demonstrated for USP30 and USP30 is therefore a potential target for anti-cancer therapy.
  • the ubiquitin-proteasome system has gained interest as a target for the treatment of cancer following the approval of the proteasome inhibitor bortezomib (Velcade®) for the treatment of multiple myeloma. Extended treatment with bortezomib is limited by its associated toxicity and drug resistance. However, therapeutic strategies that target specific aspects of the ubiquitin-proteasome pathway upstream of the proteasome, such as DUBs, are predicted to be better tolerated (Bedford et al, 2011, Nature Rev 10:29-46).
  • Fibrotic diseases including renal, hepatic and pulmonary fibrosis, are a leading cause of morbidity and mortality and can affect all tissues and organ systems. Fibrosis is considered to be the result of acute or chronic stress on the tissue or organ, characterized by extracellular matrix deposition, reduction of vascular/tubule/duct/airway patency and impairment of function ultimately resulting in organ failure. Many fibrotic conditions are promoted by lifestyle or environmental factors; however, a proportion of fibrotic conditions can be initiated through genetic triggers or indeed are considered idiopathic (i.e. without a known cause).
  • Certain fibrotic disease such as idiopathic pulmonary fibrosis (IPF) can be treated with non-specific kinase inhibitor (nintedanib) or drugs without a well- characterized mechanism of action (pirfenidone).
  • nintedanib non-specific kinase inhibitor
  • pirfenidone drugs without a well- characterized mechanism of action
  • Other treatments for organ fibrosis such as kidney or liver fibrosis, alleviate pressure on the organ itself (e.g. beta blockers for cirrhosis, angiotensin receptor blockers for chronic kidney disease). Attention to lifestyle factors, such as glucose and diet control, may also influence the course and severity of disease.
  • Mitochondrial dysfunction has been implicated in a number of fibrotic diseases, with oxidative stress downstream of dysfunction being the key pathogenic mediator, alongside decreased ATP production.
  • disruption of the mitophagy pathway through mutation or knockout of either parkin or PINK1 exacerbates lung fibrosis and kidney fibrosis, with evidence of increased oxidative stress.
  • Falgueyret et al, 2001, J.Med.Chem. 44, 94-104, and PCT application WO 01/77073 refer to cyanopyrrolidines as inhibitors of Cathepsins K and L, with potential utility in treating osteoporosis and other bone-resorption related conditions.
  • PCT application WO 2015/179190 refers to N-acylethanolamine hydrolysing acid amidase inhibitors, with potential utility in treating ulcerative colitis and Crohn’s disease.
  • PCT application WO 2013/030218 refers to quinazolin-4-one compounds as inhibitors of ubiquitin specific proteases, such as USP7, with potential utility in treating cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
  • PCT applications WO 2015/017502 and WO 2016/019237 refer to inhibitors of Bruton’s tyrosine kinase with potential utility in treating disease such as autoimmune disease, inflammatory disease and cancer.
  • PCT applications WO 2009/026197, WO 2009/129365, WO 2009/129370, and WO 2009/129371 refer to cyanopyrrolidines as inhibitors of Cathepsin C with potential utility in treating COPD.
  • United States patent application US 2008/0300268 refers to polyaromatic compounds as inhibitors of tyrosine kinase receptor PDGFR.
  • PCT applications WO 2019/222468 and WO 2019/071073 refer to cyanamide-containing compounds as USP30 inhibitors.
  • PCT application WO 2015/183987 refers to pharmaceutical compositions comprising deubiquitinase inhibitors and human serum albumin in methods of treating cancer, fibrosis, an autoimmune disease or condition, an inflammatory disease or condition, a neurodegenerative disease or condition or an infection.
  • deubiquitinases including UCHL5/UCH37, USP4, USP9X, USP11 and USP15, are said to have been implicated in the regulation of the TGF-beta signalling pathway, the disruption of which gives rise to neurodegenerative and fibrotic diseases, autoimmune dysfunction and cancer.
  • PCT application WO 2006/067165 refers to a method for treating fibrotic diseases using indolinone kinase inhibitors.
  • PCT application WO 2007/119214 refers to a method for treating early stage pulmonary fibrosis using an endothelin receptor antagonist.
  • PCT application WO 2012/170290 refers to a method for treating fibrotic diseases using THC acids.
  • PCT application WO 2018/213150 refers to sulfonamide USP30 inhibitors with potential utility in the treatment of conditions involving mitochondrial defects. Larson-Casey et al, 2016, Immunity 44, 582-596, concerns macrophage Akt1 kinase-mediated mitophagy, apoptosis resistance and pulmonary fibrosis. Tang et al, 2015, Kidney Diseases 1, 71-79, reviews the potential role of mitophagy in renal pathophysiology.
  • Acute Kidney Injury is defined as an abrupt decrease in kidney function occurring over 7 days or less, with severity of injury staged based on increased serum creatinine (SCr) and decreased urine output as described in the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
  • AKI occurs in about 13.3 million people per year, 85% of whom live in the developing world and it is thought to contribute to about 1.7 million deaths every year (Mehta et al, 2015, Lancet 385(9987): 2616-2643).
  • AKI more than likely results in permanent kidney damage (i.e., chronic kidney disease; CKD) and may also result in damage to non-renal organs.
  • CKD chronic kidney disease
  • AKI is a significant public health concern particularly when considering the absolute number of patients developing incident CKD, progressive CKD, end-stage renal disease and cardiovascular events.
  • AKI and CKD are viewed as a continuum on the same disease spectrum (Chawla et al, 2017, Nat Rev Nephrol 13(4): 241-257). Patients undergoing coronary artery bypass graft (CABG) are at high risk for kidney injury. There is an obvious unmet medical need in the development of medicinal products for the treatment and/or prevention of AKI.
  • the kidney is a site of high metabolic demand, with high mitophagy rates demonstrated in vivo (McWilliams et al, 2018, Cell Metab 27(2): 439-449 e435). Renal Proximal Tubule Epithelial Cells (RPTECs), a cell type with significant ATP requirement for solute/ion exchange, are rich in mitochondria and are the primary effector cells of Acute Kidney Injury (AKI) in the kidney.
  • RPTECs Renal Proximal Tubule Epithelial Cells
  • Mitochondrial dysfunction has been implicated in AKI/CKD mechanisms, both through multiple lines of evidence from preclinical AKI and CKD models and also through data demonstrating abnormal mitochondrial phenotypes in patient biopsies (Emma et al, 2016, Nat Rev Nephrol 12(5): 267-280; Eirin et al, 2017, Handb Exp Pharmacol 240: 229-250). Furthermore, Primary mitochondrial disease often manifest in renal symptoms, such as focal segmental glomerulosclerosis (Kawakami et al, 2015, J Am Soc Nephrol 26(5): 1040-1052) in patients with MELAS/MIDD, and also primary tubular pathologies in patients with Coenzyme Q deficiencies. Mutations in mtDNA can cause maternally inherited tubulointerstitial disease (Connor et al, 2017, PLoS Genet 13(3): e1006620).
  • Parkin knockout animals show exacerbated lung fibrosis in response to bleomycin (Kobayashi et al, 2016, J Immunol, 197:504-516).
  • airway epithelial cells from parkin knockout (KO) animals show exacerbated fibrotic and senescent responses to cigarette smoke (Araya et al, 2019, Autophagy 15(3): 510-526).
  • Preclinical models are available to study potential novel therapeutics, through their ability to model fibrosis pathology (e.g. collagen deposition) consistent with the human condition.
  • Preclinical models can be toxin-mediated (e.g. bleomycin for lung and skin fibrosis), surgical (e.g. ischemia/reperfusion injury model and unilateral ureter obstruction model for acute tubulointerstitial fibrosis), and genetic (e.g. diabetic (db/db) mice for diabetic nephropathy).
  • IPF treatments nintedanib and pirfenidone
  • the present invention is directed to compounds of formula (I):
  • R1 is selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )fluoroalkyl, CH 2 OCH 3 and CH 2 N(CH 3 ) 2 ;
  • R2 is selected from hydrogen and methyl
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • the present invention is also directed to uses of the compounds of formula (I), particularly in the treatment of conditions involving mitochondrial dysfunction, cancer and fibrosis, and also processes for the preparation thereof and pharmaceutical compositions containing said compounds.
  • the present invention is directed to USP30 inhibitors that have suitable and/or improved properties in order to maximise efficacy against the target disease.
  • properties include, for example, potency, selectivity, physicochemical properties, ADME (absorption, distribution, metabolism and excretion) properties, including PK (pharmacokinetic) profile, and safety profile.
  • USP30 is a transmembrane protein located in the outer membrane of mitochondria, which are energy- producing organelles present inside cells. Therefore, being able to demonstrate cellular activity in vitro is advantageous, as this is one of a number of components that may indicate a greater ability to engage the target in its physiological setting, i.e. where the USP30 inhibitor compound is able to penetrate cells.
  • the USP30 cellular western blot (WB) assay described herein aims to test the activity of compounds against USP30 in cells using an irreversible activity probe to monitor USP30 activity.
  • target engagement assessment (ex vivo) may be carried out in either brain or kidney tissue samples from compound-dosed animals using the assay described herein.
  • TOM20 an outer mitochondrial membrane protein
  • DUB enzymes for which the compounds of the present invention may be screened against are UCHL1, UCHL3, UCHL5, YOD1, SENP2, SENP6, TRABID, BAP1, Cezanne, MINDY2/FAM63B, OTU1, OTUD3, OTUD5, OTUD6A, OTUD6B, OTUB1/UBCH5B, OTUB2, CYLD, VCPIP, AMSH-LP, JOSD1, JOSD2, USP1/UAF1, USP2, USP4, USP5, USP6, USP7, USP8, USP9x, USP10, USP11, USP12/UAF1, USP13, USP14, USP15, USP16, USP19, USP20, USP21, USP22, USP24, USP25, USP28, USP32, USP34, USP35, USP36, USP45, USP46/UAF1, USP47 and USP48.
  • compounds of the invention have good
  • targets for which the compounds of the present invention may be screened against are those of the industry standard Eurofins-Cerep SafetyScreen44 panel, which includes 44 targets as a representative selection of GPCR receptors, transporters, ion channels, nuclear receptors, and kinase and non-kinase enzymes.
  • compounds of the invention have insignificant affinity against targets of this screening panel.
  • targets for which the compounds of the present invention may be screened against are kinases of the Thermo Fisher SelectScreen kinase profiling panel, which includes 39 targets as a representative selection of kinase enzymes.
  • compounds of the invention have insignificant affinity against targets of this screening panel.
  • examples of a particular enzyme class for which the compounds of the present invention may be screened against are the cathepsins (e.g. cathepsin A, B, C, H, K, L, L2, S, V and Z).
  • cathepsins e.g. cathepsin A, B, C, H, K, L, L2, S, V and Z.
  • compounds of the invention have good selectivity for USP30 over one or more of these enzymes.
  • An orally administered drug should have good bioavailability; that is an ability to readily cross the gastrointestinal (GI) tract and not be subject to extensive metabolism as it passes from the GI tract into the systemic circulation. Once a drug is in the systemic circulation the rate of metabolism is also important in determining the time of residence of the drug in the body.
  • GI gastrointestinal
  • the Caco-2 assay is a widely accepted model for predicting the ability of a given molecule to cross the GI tract.
  • the majority of metabolism of drug molecules generally occurs in the liver, and in vitro assays using whole cell hepatocytes (animal or human) are widely accepted methods for measuring the susceptibility of a given molecule towards metabolism in the liver.
  • Such assays aim to predict in vivo clearance from the hepatocyte calculated clearance value.
  • Compounds which have good Caco-2 flux and are stable towards hepatocytes are predicted to have good oral bioavailability (good absorption across the GI tract and minimal extraction of compound as it passes through the liver) and a long residence time in the body that is sufficient for the drug to be efficacious.
  • the solubility of a compound is an important factor in achieving a desired concentration of drug in systemic circulation for the anticipated pharmacological response.
  • Low aqueous solubility is a problem encountered with formulation development of new chemical entities and to be absorbed a drug must be present in the form of solution at the site of absorption.
  • the kinetic solubility of a compound may be measured using a turbidimetric solubility assay, the data from which may also be used in conjunction with Caco-2 permeability data to predict dose dependent human intestinal absorption.
  • parameters that may be measured using standard assays that are indicative of a compound’s exposure profile include, for example plasma stability (half-life measurement), blood AUC, C max , C min and T max values.
  • CNS disorders including Alzheimer’s disease, Parkinson’s disease, and other disorders described herein
  • USP30 inhibitors that possess effective blood brain penetration properties and provide suitable residence time in the brain to be efficacious.
  • the probability that a compound can cross the blood brain barrier may be measured by an in vitro flux assay utilizing a MDR1-MDCK cell monolayer (Madin-Darby Canine Kidney cells transfected with MDR-1 resulting in overexpression of the human efflux transporter P-glycoprotein). Additionally, exposure may also be measured directly in brain and plasma using in vivo animal models.
  • a cell toxicity counter-screen may be used to assay the anti-proliferative/cytotoxic effect in a particular cell line (e.g. HCT116) by fluorometric detection of rezasurin (alamarBlue) to resofurin in response to mitochondrial activity.
  • Toxicology and safety studies may also be conducted to identify potential target organs for adverse effects and define the Therapeutic Index to set the initial starting doses in clinical trials. Regulatory requirements generally require studies to be conducted in at least two laboratory animal species, one rodent (rat or mouse) and one nonrodent (rabbit, dog, non-human primate, or other suitable species).
  • the bacterial reverse mutation assay (Ames Test) may be used to evaluate the mutagenic properties of compounds of the invention, commonly by using the bacterial strain Salmonella typhimurium, which is mutant for the biosynthesis of the amino acid histidine.
  • micronucleus assay may be used to determine if a compound is genotoxic by evaluating the presence of micronuclei.
  • Micronuclei may contain chromosome fragments produced from DNA breakage (clastogens) or whole chromosomes produced by disruption of the mitotic apparatus (aneugens).
  • the hERG predictor assay provides valuable information about the possible binding of test compounds to the potassium channel and potential QT prolongation on echocardiogram. Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia (Torsades de Pointes).
  • assay data may be generated from an automated patch-clamp assay platform.
  • the present invention is therefore directed to USP30 inhibitors that have suitable and/or improved properties in order to maximise efficacy against the target disease.
  • properties include, for example, potency, selectivity, physicochemical properties, ADME (absorption, distribution, metabolism and excretion) properties, including PK (pharmacokinetic) profile, and safety profile.
  • ADME absorption, distribution, metabolism and excretion
  • PK pharmacokinetic profile
  • the compounds of the present invention have been found to demonstrate one or more of the above identified advantages over reference examples from the prior art sharing some structural similarity that are both significant and unexpected. For instance, all of the Examples of the present invention are significantly more potent for USP30 than the Reference Examples as measured in the biochemical assay described herein. All of the Examples of the present invention are significantly more selective for USP30 over other DUBs.
  • the present invention provides a compound of formula (I):
  • R1 is selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )fluoroalkyl, CH 2 OCH 3 and CH 2 N(CH 3 ) 2 ;
  • R2 is selected from hydrogen and methyl
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • Alkyl groups may be straight or branched and contain 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and sec-butyl.
  • Fluoroalkyl groups may contain one or more fluorine substituents. Examples are fluoromethyl, difluoromethyl and trifluoromethyl. Unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be selected from more than one alternative, the selected groups may be the same or different. The term‘independently’ means that where more than one substituent is selected from more than one possible substituent, those substituents may be the same or different.
  • R1 is selected from methyl, CH 2 F, CHF 2 , CF 3 , CH 2 OCH 3 and CH 2 N(CH 3 ) 2 .
  • R1 is selected from methyl and CH 2 OCH 3 .
  • R1 is methyl
  • R1 is CH 2 OCH 3 .
  • R2 is hydrogen
  • R3 is hydrogen
  • R4 is selected from hydrogen and fluorine.
  • R4 is hydrogen
  • R5 is selected from hydrogen and fluorine.
  • R5 is hydrogen
  • R6 is hydrogen
  • R1 is selected from methyl and CH2OCH3;
  • R2 is hydrogen
  • R3 is hydrogen
  • R4 is selected from hydrogen and fluorine
  • R5 is selected from hydrogen and fluorine
  • R6 is hydrogen
  • R1 is (C1-C4)alkyl
  • R2 is selected from hydrogen and methyl
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • R1 is methyl
  • R2 is selected from hydrogen and methyl
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • R1 is methyl
  • R2 is hydrogen; and R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • R1 is methyl
  • R2 is hydrogen
  • R3 is hydrogen
  • R4 is selected from hydrogen and fluorine
  • R5 is selected from hydrogen and fluorine
  • R6 is hydrogen
  • R1 is CH 2 OCH 3 ;
  • R2 is selected from hydrogen and methyl
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • R1 is CH 2 OCH 3 ;
  • R2 is hydrogen
  • R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
  • R1 is CH 2 OCH 3 ;
  • R2 is hydrogen
  • R3 is hydrogen
  • R4 is selected from hydrogen and fluorine
  • R5 is selected from hydrogen and fluorine
  • R6 is hydrogen
  • Preferred compounds of formula (I) for use in the present invention are selected from:
  • Pharmaceutical acceptable salts of the compounds of formula (I) include the acid addition and base salts (including di-salts) thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate, camsylate, citrate, edisylate, esylate, fumarate, gluceptate, gluconate, glucuronate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, hydrogen phosphate, isethionate, D- and L-lactate, malate, maleate, malonate, mesylate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, palmate, phosphate, saccharate, stearate, succinate sulfate, D-and L-tartrate, and tosylate salts.
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, ammonium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • a pharmaceutical acceptable salt of a compound of formula (I) may be readily prepared by mixing together solutions of the compound of formula (I) and the desired acid or base, as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • Pharmaceutical acceptable solvates in accordance with the invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, acetone-d6, DMSO-d6.
  • clathrates drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in non-stoichiometric amounts.
  • references to compounds of formula (I) include references to salts thereof and to solvates and clathrates of compounds of formula (I) and salts thereof.
  • the invention includes all polymorphs of the compounds of formula (I) as hereinbefore defined. Also, within the scope of the invention are so-called “prodrugs" of the compounds of formula (I). Thus, certain derivatives of compounds of formula (I) which have little or no pharmacological activity themselves can, when metabolised upon administration into or onto the body, give rise to compounds of formula (I) having the desired activity. Such derivatives are referred to as "prodrugs”.
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as "pro-moieties” as described, for example, in “Design of Prodrugs” by H Bundgaard (Elsevier, 1985).
  • racemate or the racemate of a salt or derivative
  • HPLC high performance liquid chromatography
  • the racemate or a racemic precursor
  • a suitable optically active compound for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine.
  • the present invention includes all crystal forms of the compounds of formula (I) including racemates and racemic mixtures (conglomerates) thereof. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994).
  • the compounds of formula (I) contain two chiral centres at the carbon atoms of the pyrrolidine ring that are substituted by R1 and the amide and said stereocentres could exist in either the (R) or (S) configuration.
  • the compounds of formula (I) of the present invention exist as a single stereoisomer.
  • the pyrrolidine carbon atom of the amide substituent exists as the (R)-stereocentre, whereas the designation of the pyrrolidine carbon atom of the R1 group is dependent on the nature of the substituent.
  • the compound of formula (I) is isolated as a single stereoisomer and may exist with a stereoisomeric excess of at least 60%, preferably at least 80%, more preferably at least 90%, more preferably at least 95%, for example 96%, 97%, 98%, 99%, or 100%.
  • the present invention also includes all pharmaceutically acceptable isotopic variations of a compound of formula (I).
  • An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 13C and 14C, nitrogen, such as 15N, oxygen, such as 17O and 18O, phosphorus, such as 32P, sulfur, such as 35S, fluorine, such as 18F, and chlorine, such as 36CI. Substitution of the compounds of the invention with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half- life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Certain isotopic variations of the compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, and 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • Isotopic variations of the compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using appropriate isotopic variations of suitable reagents.
  • the compounds of formula (I) are inhibitors of the deubiquitylating enzyme USP30.
  • the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer for use as a medicament.
  • the present invention provides a method of treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect, in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.
  • the present invention provides the use of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for the treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect.
  • the manufacture of a medicament may include, inter alia, the chemical synthesis of the compound of formula (I) or a salt thereof, or the preparation of a composition or formulation comprising the compound or salt, or the packaging of any medicament comprising the compound.
  • the disorder or condition benefiting from USP30 activity is selected from a condition involving mitochondrial dysfunction, cancer and fibrosis.
  • the disorder or condition benefiting from USP30 activity is a condition involving mitochondrial dysfunction.
  • Mitochondrial dysfunctions result from defects of the mitochondria, which are specialized compartments present in every cell of the body except red blood cells. When mitochondria fail, less and less energy is generated within the cell and cell injury or even cell death will follow. If this process is repeated throughout the body the life of the subject in whom this is happening is severely compromised. Diseases of the mitochondria appear most often in organs that are very energy demanding such as the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory system.
  • the condition involving mitochondrial dysfunction may be selected from a condition involving a mitophagy defect, a condition involving a mutation in mitochondrial DNA, a condition involving mitochondrial oxidative stress, a condition involving a defect in mitochondrial membrane potential, mitochondrial biogenesis, a condition involving a defect in mitochondrial shape or morphology, and a condition involving a lysosomal storage defect.
  • the condition involving mitochondrial dysfunction may be selected from a neurodegenerative disease; multiple sclerosis (MS); mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome; materially-inherited diabetes and deafness (MIDD); Leber's hereditary optic neuropathy (LHON); cancer (including, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, and non-small cell lung carcinoma); neuropathy, ataxia, retinitis pigmentosa, maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes; diabetic
  • the condition involving mitochondrial dysfunction may be a CNS disorder, for example a neurodegenerative disease.
  • Neurodegenerative diseases include, but are not limited to, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia.
  • Parkinson’s disease Alzheimer’s disease
  • ALS amyotrophic lateral sclerosis
  • Huntington’s disease ischemia
  • stroke dementia with Lewy bodies
  • MSA multiple system atrophy
  • PSP progressive supranuclear palsy
  • CBD corticobasal degeneration
  • frontotemporal dementia frontotemporal dementia
  • the compounds of the invention may be useful in the treatment or prevention of Parkinson’s disease, including, but not limited to, PD related to mutations in a-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease (AR-JP) where parkin is mutated.
  • Parkinson’s disease including, but not limited to, PD related to mutations in a-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease (AR-JP) where parkin is mutated.
  • the compounds of the invention or pharmaceutical compositions thereof as described herein may be combined with one or more additional agents when used for the treatment or prevention of conditions involving mitochondrial dysfunction.
  • the compounds may be combined with one or more additional agents selected from levodopa, a dopamine agonist, a monoamino oxygenase (MAO) B inhibitor, a catechol O-methyltransferase (COMT) inhibitor, an anticholinergic, riluzole, amantadine, a cholinesterase inhibitor, memantine, tetrabenazine, an antipsychotic, diazepam, clonazepam, an antidepressant, and an anti-convulsant.
  • additional agents selected from levodopa, a dopamine agonist, a monoamino oxygenase (MAO) B inhibitor, a catechol O-methyltransferase (COMT) inhibitor, an anticholinergic, riluzole, amantadine,
  • the compounds may be combined with agents which reduce/remove pathogenic protein aggregates in neurodegenerative diseases, such as agents which reduce/remove alpha-synuclein in Parkinson’s disease, multiple system atrophy or dementia with Lewy bodies; agents which reduce/remove Tau in Alzheimer’s disease or progressive supranuclear palsy; agents which reduce/remove TDP-43 in ALS or frontotemporal dementia.
  • the disorder or condition benefiting from USP30 activity is cancer.
  • the cancer may be linked to mitochondrial dysfunction.
  • Preferred cancers include, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, and non-small cell lung carcinoma.
  • lymphoma and leukaemia multiple myeloma
  • metastatic carcinoma osteosarcoma
  • chondosarcoma chondosarcoma
  • Ewing’s sarcoma nasopharyngeal carcinoma
  • colorectal cancer colorectal cancer
  • non-small cell lung carcinoma non-small cell lung carcinoma
  • the compounds of the invention may be useful in the treatment or prevention of cancer where apoptotic pathways are dysregulated and more particularly where proteins of the BCL-2 family are mutated, or over or under expressed.
  • Fibrosis refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia.
  • Fibrotic disorders that may be treated by the compounds and compositions of the present invention include, inter alia, fibrosis/fibrotic disorders associated with major organ diseases, for example, interstitial lung disease (ILD), liver cirrhosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (hepatic fibrosis), kidney disease (renal fibrosis), acute kidney injury (AKI), chronic kidney disease (CKD), delayed kidney graft function, heart or vascular disease (cardiac fibrosis) and diseases of the eye; fibroproliferative disorders, for example, systemic and local scleroderma, keloids and hypertrophic scars, atherosclerosis, restenosis, and Dupuytren’s contracture; scarring associated with trauma, for example, surgical
  • the present invention therefore relates to methods of treatment or prevention, and compounds and compositions used in said methods, of fibrosis/fibrotic disorders of and/or associated with the major organs, including for example, the lung, liver, kidney, heart, skin, eye, gastrointestinal tract, peritoneum and bone marrow, and other diseases/disorders herein described.
  • the compounds may be combined with agents which are used as treatments for kidney disease, including anti-diabetic agents, cardiovascular disease agents, and novel agents targeting disease relevant pathways such as oxidative stress (including, but not limited to, the nrf2/keap-1 pathway) and anti-apoptotic pathways (including, but not limited to, anti p53 agents).
  • agents which are used as treatments for kidney disease including anti-diabetic agents, cardiovascular disease agents, and novel agents targeting disease relevant pathways such as oxidative stress (including, but not limited to, the nrf2/keap-1 pathway) and anti-apoptotic pathways (including, but not limited to, anti p53 agents).
  • Interstitial lung disease includes disorders in which pulmonary inflammation and fibrosis are the final common pathways of pathology, for example, sarcoidosis, silicosis, drug reactions, infections and collagen vascular diseases, such as rheumatoid arthritis and systemic sclerosis (scleroderma).
  • the fibrotic disorder of the lung includes, for example, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis (UIP), interstitial lung disease, cryptogenic fibrosing alveolitis (CFA), bronchiolitis obliterans, and bronchiectasis.
  • Idiopathic pulmonary fibrosis is the most common type of ILD and has no known cause.
  • the compounds may be combined with agents which are treatments for IPF and potentially for ILD, including nintedanib and pirfenidone.
  • Liver cirrhosis has similar causes to ILD and includes, for example, cirrhosis associated with viral hepatitis, schistosomiasis and chronic alcoholism.
  • Kidney disease may be associated with diabetes, which can damage and scar the kidneys leading to a progressive loss of function, and also hypertensive diseases.
  • Kidney fibrosis may occur at any stage of kidney disease, from chronic kidney disease (CKD), such as incident CKD and progressive CKD, through to end-stage renal disease (ESRD).
  • Kidney fibrosis can develop as a result of cardiovascular disease such as hypertension or diabetes, both of which place immense strain on kidney function which promotes a fibrotic response.
  • kidney fibrosis can also be idiopathic (without a known cause), and certain genetic mitochondrial diseases also present kidney fibrosis manifestations and associated symptoms.
  • Heart disease may result in scar tissue that can impair the ability of the heart to pump.
  • Diseases of the eye include, for example, macular degeneration and retinal and vitreal retinopathy, which can impair vision.
  • the present invention is directed to the treatment or prevention of idiopathic pulmonary fibrosis (IPF).
  • IPF idiopathic pulmonary fibrosis
  • the present invention is directed to the treatment or prevention of kidney fibrosis.
  • the present invention is directed to the treatment or prevention of acute kidney injury (AKI), especially in high risk patients.
  • AKI acute kidney injury
  • organ transplantation such as due to ischemia reperfusion injury, delayed graft function
  • oncology such as AKI due to chemotherapy
  • contrast medium-induced nephropathy such as direct- tubular cytotoxicity, hemodynamic ischemia and osmotic effects
  • acute interstitial nephritis such as due to drugs or infection.
  • a particular high risk patient sub-group are those undergoing cardiac surgery, for example, coronary artery bypass graft and/or valve surgery.
  • the present invention is directed to the treatment or prevention of chronic kidney disease (CKD) stemming from such AKI, including for example, tubulointerstitial fibrosis and diabetic nephropathy.
  • CKD chronic kidney disease
  • Leigh Syndrome is a rare inherited neurometabolic disorder that affects the central nervous system. This progressive disorder begins in infants between the ages of three months and two years. Rarely, it occurs in teenagers and adults. Leigh Syndrome can be caused by mutations in nuclear DNA encoding for mitochondrial proteins, mutations in mitochondrial DNA (maternally inherited leigh syndrome– MILS), or by deficiencies of an enzyme called pyruvate dehydrogenase located on the short arm of the X Chromosome (X-linked Leigh syndrome). Symptoms of Leigh syndrome usually progress rapidly. The earliest signs may be poor sucking ability, and the loss of head control and motor skills. These symptoms may be accompanied by loss of appetite, vomiting, irritability, continuous crying, and seizures. As the disorder progresses, symptoms may also include generalized weakness, lack of muscle tone, and episodes of lactic acidosis, which can lead to impairment of respiratory and kidney function.
  • MILS maternally inherited Leigh syndrome
  • genetic mutations in mitochondrial DNA interfere with the energy sources that run cells in an area of the brain that plays a role in motor movements.
  • Genetic mutations in mitochondrial DNA result in a chronic lack of energy in these cells, which in turn affects the central nervous system and causes progressive degeneration of motor functions.
  • NARP neuropathy ataxia and retinitis pigmentosa
  • Leigh X-linked Leigh's disease
  • Leigh syndrome exists which is called French Canadian Variant, characterized by mutations in a gene called LRPPRC. Similar neurological symptoms are expressed as those for Leigh Syndrome, although Liver Steatosis is commonly also observed in the French Canadian Variant.
  • the present invention is directed to the treatment or prevention of Leigh syndrome or disease, including for example, X-linked Leigh's disease, Leigh Syndrome French Canadian Variant, and/or the symptoms associated with Leigh’s disease.
  • the compounds may be combined with novel agents which may be used as treatments for mitochondrial disease, including, but not limited to, nicotinamide riboside.
  • references to‘treatment’ includes means to ameliorate, alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis.
  • the compounds of the invention are useful in the treatment of the diseases disclosed herein in humans and other mammals.
  • the invention encompasses prophylactic therapy of the diseases disclosed herein and includes means to prevent or slow the appearance of symptoms of the named disorder or condition.
  • the compounds of the invention are useful in the prevention of the diseases disclosed herein in humans and other mammals.
  • a patient in need of treatment or prevention may, for example, be a human or other mammal suffering from the condition or at risk of suffering from the condition.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of said compound or tautomer, together with a pharmaceutically acceptable diluent or carrier.
  • compositions of the invention comprise any of the compounds of the invention combined with any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • pharmaceutically acceptable carriers include, but are not limited to, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms.
  • the compositions may be in the form of, for example, tablets, capsules, powders, granules, elixirs, lozenges, suppositories, syrups and liquid preparations including suspensions and solutions.
  • composition in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers.
  • the composition may further contain ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms.
  • the compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents.
  • the compounds may be combined with an additional anti-tumour therapeutic agent, for example, chemotherapeutic drugs or inhibitors of other regulatory proteins.
  • the additional anti-tumour therapeutic agent is a BH-3 mimetic.
  • BH-3 mimetics may be selected from but not limited to one or more of ABT-737, ABT-199, ABT-263, and Obatoclax.
  • the additional anti-tumour agent is a chemotherapeutic agent.
  • Chemotherapeutic agents may be selected from but not limited to, olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin, ionizing radiation (IR), camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-fluoropyrimidines, gemcitabine, and doxorubicin.
  • the compounds of the invention or pharmaceutical compositions thereof, as described herein may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, LTD4 antagonists, EGFR inhibitors and endothelin antagonists.
  • additional pharmaceutical agents selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, LTD4 antagonists, EGFR inhibitors and endothelin antagonists.
  • the compounds of the invention or pharmaceutical compositions thereof, as described herein may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of general immunosuppressive drugs, such as a corticosteroid, immunosuppressive or cytotoxic agents, or antifibrotics, such as pirfenidone or a non-specific kinase inhibitor (e.g. nintedanib).
  • general immunosuppressive drugs such as a corticosteroid, immunosuppressive or cytotoxic agents, or antifibrotics, such as pirfenidone or a non-specific kinase inhibitor (e.g. nintedanib).
  • compositions of the invention may be administered in any suitably effective manner, such as oral, parenteral, topical, inhaled, intranasal, rectal, intravaginal, ocular and aural.
  • Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in "Remington's Pharmaceutical Sciences", 19th Edition (Mack Publishing Company, 1995).
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi-and nano- particulates, gels, films (including muco- adhesive), ovules, sprays and liquid formulations.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001).
  • a typical tablet may be prepared using standard processes known to a formulation chemist, for example, by direct compression, granulation (dry, wet, or melt), melt congealing, or extrusion.
  • the tablet formulation may comprise one or more layers and may be coated or uncoated.
  • excipients suitable for oral administration include carriers, for example, cellulose, calcium carbonate, dibasic calcium phosphate, mannitol and sodium citrate, granulation binders, for example, polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethylcellulose and gelatin, disintegrants, for example, sodium starch glycolat and silicates, lubricating agents, for example, magnesium stearate and stearic acid, wetting agents, for example, sodium lauryl sulfate, preservatives, anti-oxidants, flavours and colourants.
  • carriers for example, cellulose, calcium carbonate, dibasic calcium phosphate, mannitol and sodium citrate
  • granulation binders for example, polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethylcellulose and gelatin
  • disintegrants for example, sodium starch glycolat and silicates
  • lubricating agents for example, magnesium stearate and stearic acid
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled dual-, targeted and programmed release. Details of suitable modified release technologies such as high energy dispersions, osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25 (2), 1-14 (2001). Other modified release formulations are described in US Patent No.6,106,864.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9)
  • a suitable vehicle such as sterile, pyrogen-free water.
  • parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • compositions of formula (I) used in the preparation of parenteral solutions may be increased by suitable processing, for example, the use of high energy spray-dried dispersions and/or by the use of appropriate formulation techniques, such as the use of solubility-enhancing agents.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed, sustained, pulsed, controlled dual, targeted and programmed release.
  • Pharmaceutical compositions of the present invention also include compositions and methods known in the art for bypassing the blood brain barrier or can be injected directly into the brain. Suitable areas for injection include the cerebral cortex, cerebellum, midbrain, brainstem, hypothalamus, spinal cord and ventricular tissue, and areas of the PNS including the carotid body and the adrenal medulla.
  • the magnitude of an effective dose of a compound will, of course, vary with the nature of the severity of the condition to be treated and the route of administration. The selection of appropriate dosages is within the remit of the physician.
  • the daily dose range is about 10mg to about 100 mg per kg body weight of a human and non-human animal and in general may be around 10mg to 30mg per kg body weight per dose. The above dose may be given from one to three times per day.
  • oral administration may require a total daily dose of from 5mg to 1000mg, such as from 5 to 500mg, while an intravenous dose may only require from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
  • the total daily dose may be administered in single or divided doses.
  • the present invention provides a process for the preparation of a compound of formula (I) comprising reacting a compound of formula (IV), where X is OH with an amine of formula (V), where PG is a protecting group, such as BOC or CBZ, to give an amide of formula (III) (Scheme 1).
  • the amide-coupling reaction can be performed using standard methodology, for example by reaction using a coupling reagent such as DCC, HATU, HBTU, EDC or via a mixed anhydride.
  • the acid (IV), where X is OH can be converted into the acid chloride (IV), where X is Cl, using SOCl2, PCl3, or PCl5, which can then be reacted with the amine (V), preferably in a suitable solvent in the presence of a suitable base.
  • the compound (IV), where X forms the ester can be reacted directly with the amine (V), preferably in a suitable solvent.
  • the compound of formula (III) may be deprotected using standard methods to give amine (II) which may then be reacted with cyanogen bromide to give the corresponding compound of formula (I).
  • the present invention provides a compound, which is selected from formulae (II) and (III):
  • PG is a protecting group, preferably BOC or CBZ, and R1, R2, R3, R4, R5 and R6 are as defined herein for the compound of formula (I) and preferred embodiments thereof, a tautomer thereof, or a salt of said compound or tautomer.
  • Ethyl 5-(3-cyanophenyl) oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-cyanophenyl)-2-oxoethyl)amino)-2-oxoacetate (130 g, 500 mmol) in POCl 3 (390 mL, 3 volumes) was heated at 100 °C for 16 h. The mixture was cooled to rt and concentrated under reduced pressure, then poured into ice-cold water (2000 mL), basified with solid NaHCO 3 to pH 8 and extracted with ethyl acetate (2 x 2000 mL).
  • the mixture was heated at 100 °C for 16 h, then cooled to rt, acidified with 2N HCl (60 mL) and stirred at rt for 3 h before neutralizing with NaHCO 3 solution (pH 7 to 8).
  • the mixture was extracted with EtOAc (3 x 120 mL) and the organic phases were combined, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • the crude material was purified by column chromatography (20% EtOAc in hexane) to obtain 3-acetyl-5- fluorobenzonitrile (1.1 g, 4.56 mmol, 67 % yield).
  • Dilution plates were prepared at 21 times the final concentration (2100 ⁇ M for a final concentration of 100 ⁇ M) in 50% DMSO in a 96-well polypropylene V-bottom plate (Greiner #651201). A typical 8-point dilution series would be 100, 30, 10, 3, 1, 0.3, 0.1, 0.03 ⁇ M final. Reactions were performed in duplicate in black 384 well plates (small volume, Greiner 784076) in a final reaction volume of 21 ⁇ l. Either 1 ⁇ l of 50% DMSO or diluted compound was added to the plate.
  • USP30 (Boston Biochem #E582) was diluted in reaction buffer (40mM Tris, pH 7.5, 0.005% Tween 20, 0.5mg/ml BSA, 5 mM beta-mercaptoethanol) to achieve a final assay concentration of 4 nM, and 10 ⁇ l of diluted USP30 was added to the compound. Enzyme and compound were incubated for 30 min at room temp. Reactions were initiated by the addition of 50nM of TAMRA labelled peptide linked to ubiquitin via an iso-peptide bond as fluorescence polarisation substrate. Reactions were read immediately after addition of substrate and following a 2-hour incubation at room temperature. Readings were performed on a Pherastar Plus (BMG Labtech). l Excitation 540 nm; l Emission 590 nm.
  • Examples 1 and 6 were subject to pharmacological profiling in the Eurofins CEREP SafetyScreen44 panel. At a single concentration of 10 mM, less than 50% inhibition of binding or enzyme activity was observed against all targets in the panel for both compounds, apart from MAO-A for Example 1, which showed inhibition of 72%.
  • Example 1 was subject to pharmacological profiling against 39 kinases of the Thermo Fisher SelectScreen kinase profiling panel. At a single concentration of 10 mM, less than 40% inhibition of binding or enzyme activity was observed against all targets in the panel.
  • Example 1 was screened at single concentrations of 10 mM and 1 mM against 8 cathepsins (B, C, H, K, L, L2, S, Z). The IC 50 was calculated for examples against cathepsins B, K, L, S and V.
  • Examples 1 and 6 were evaluated for effects on the hERG potassium channel, in stably expressed CHO cells at concentrations between 0.01 and 30 mM. Examples 1 and 6 produced maximum inhibition values of 30.2% and 23%, respectively, of the hERG current amplitude at 30 mM indicating little propensity for affecting the QT interval.
  • Example 1 was assessed in the bacterial reverse mutation assay (Ames) and in vitro micronucleus assay. All in vitro tests were conducted with and without exogenous metabolic activation using concentrations up to those limited by cytotoxicity or insolubility.
  • Example 1 did not induce mutations when tested up to 5000 mg/plate with and without metabolic activation in the reverse mutation assay in Salmonella typhimurium strains TA98, TA100, TA1535 and TA97a and the Escherichia Coli strain WP2 uvrA pKM101.
  • Example 1 Induction of chromosome damage was assessed using the in vitro micronucleus assay in TK6 cells.
  • Example 1 was negative for induction of micronuclei when incubated for 3 hours in the presence of exogenous metabolic activation followed by 27 hours recovery, and also when incubated for 27 hours in the absence of exogenous metabolic activation followed by 27 hours recovery.
  • Human cell lines can be challenged with mitochondrial depolarizing agents (ionophores (eg. CCCP, valinomycin), mitochondrial complex inhibitors (oligomycin, antimycin A)) to induce ubiquitylation of TOM20, which is then further promoted in the presence of USP30 inhibitors.
  • TOM20 ubiquitylation is subsequently assessed through western blotting of the cell lysates, with TOM20 ubiquitylation adduct detection possible due to an 8 kDa molecule weight increase for each molecule of ubiquitin added, resulting in laddering of a TOM20 immunoreactive band.
  • TOM20-ubiquitylation levels can be quantified using chemiluminescence densitometry of laddered immunoreactive bands.
  • TPSA topological polar surface area.
  • Turbidimetric solubility Test compound solution prepared in DMSO diluted into aqueous buffer. Turbidimetry is used as the end-point by measuring absorbance at 620 nm.
  • FaSSIF simulated intestinal fluid in fasted state measured at pH 6.5.
  • Hep Cl mouse in vitro hepatocyte clearance in mouse cells.
  • Hep Cl human in vitro hepatocyte clearance in human cells.
  • Plasma f u,p The free fraction of a compound in plasma preparation determined by in vitro equilibrium dialysis. It is understood that only unbound (free) compound is capable of engaging with the target.
  • Brain f u,br The free fraction of a compound in brain homogenate preparation determined by in vitro equilibrium dialysis. It is understood that only unbound (free) compound is capable of engaging with the target.
  • Cl u in vitro clearance.
  • Cl u as defined here is the scaled clearance, in turn calculated from the intrinsic clearance.
  • the intrinsic clearance is the predicted clearance due to hepatic metabolic reactions, determined from incubation of a compound in a hepatocyte preparation. The lower the value in mL/min/kg, the more stable the compound.
  • Cl in vivo clearance Pharmacokinetic measurement of the volume of plasma (or any matrix) from which a substance is completely removed per unit time. The lower the value in mL/min/kg, the more stable the compound.
  • Oral F Oral Bioavailability.
  • MDR1-MDCK Mesdin-Darby Canine Kidney cell monolayer
  • in vitro flux assay
  • Cell TE WB USP30 endogenous cellular target engagement western blot (WB) assay. Assays the activity of compounds against USP30 in cells using an irreversible activity probe to monitor USP30 activity.
  • TE ex vivo USP30 brain tissue target engagement assay.
  • Hela cells stably overexpressing YFP-Parkin were seeded into 6 well dishes. Once adhered, cells were treated with appropriate concentrations of test compounds or vehicle control for 1 hour at 37°C, 5% CO2.
  • Whole cell lysates were prepared by scraping the cells into cold PBS, centrifuging and lysing in lysis buffer (50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630, 2 mM MgCl2, 10% Glycerol, 5 mM beta-mercaptoethanol, cOmplete mini tablets EDTA free (Roche), PhosStop tablets (Roche)) for 10 mins.
  • lysis buffer 50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630, 2 mM MgCl2, 10% Glycerol, 5 mM beta-mercaptoethanol, cOmplete mini tablets EDTA free (Roc
  • lysis buffer 50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630, 2 mM MgCl 2 , 10% Glycerol, 5 mM beta-mercaptoethanol, cOmplete mini tablets EDTA free (Roche), PhosStop tablets (Roche)) using the Retch Mixer Mill (MM400).
  • the lysates were cleared and protein quantified using the Bradford Protein assay (Pierce). Lysate containing 60 ⁇ g protein was incubated with a final conc of 24 ⁇ M of HA-Ahx-Ahx-Ub-VME probe for 60 mins at room temperature.
  • USP30 was detected using an anti-USP30 Sheep S746D antibody (MRC PPU Reagents and Services) and a rabbit anti sheep secondary IgG (H+L) horseradish peroxidase conjugated (Thermo #31480) and visualised using ECL reagent (GE #RPN2109) on a GE LAS4000 imager.
  • Target engagement was measured by quantitation of the bands corresponding to USP30 and USP30 bound to the Ub-VME probe and expression of this proportion compared to vehicle treated control.
  • Reference Examples A, B, C and D are known DUB inhibitors that have been identified as active as inhibitors of USP30 and share some structural similarity with the compounds of the present invention, possessing the cyanamide structural feature.
  • Example D is disclosed in WO 2016/046530 as having Uchl1 inhibitory activity.
  • Example 1 is approximately 7 to 20-fold more potent than Reference Examples A, B and C, and 880-fold more potent than Reference Example D.
  • Example 6 is approximately 8 to 25-fold more potent than Reference Examples A, B and C and 1100-fold more potent than Reference Example D.
  • Examples 1, 5 and 7 are significantly more selective for USP30 over USP10, USP16, USP21, USP25 and USP28 compared to Reference Examples A and B.
  • Examples 2, 3, 4, 6 and 8 are significantly more selective for USP30 over USP10, USP16, USP21, USP25 and USP28 compared to Reference Examples A, B and C.
  • Examples 1, 4, 5, 6 and 8 are significantly more selective for USP30 over USP22, USP35 and USP46, compared to Reference Examples A, B and C.
  • Examples 2, 3 and 7 are significantly more selective for USP30 over USP22, USP35 and USP46, compared to Reference Examples A and B.
  • Examples 1 and 6 are significantly more selective for USP30 over the cathepsins (K, L and S) compared to Reference Examples A, B and C.
  • Examples 1, 4 and 6 are significantly more potent (3 3-fold, as measured in the Cell TE WB assay) for USP30 than Reference Example A.
  • Examples 1, 2, 3, 4 and 6 are significantly more potent (> 5-fold as measured in the Cell TE WB assay) for USP30 than Reference Example B.
  • Examples 1, 2, 3, 4 and 6 are significantly more potent (> 200-fold, as measured in the Cell TE WB assay) for USP30 than Reference Example C.
  • Examples 1 and 6 show significantly improved hepatocyte metabolic stability (as measured in mouse hepatocytes) compared to Reference Examples A, B and C.
  • Examples 1 and 6 show significantly improved plasma stability (26 to 400-fold and 6 to 97-fold, respectively, as measured in mouse plasma) compared to Reference Examples A, B and C.
  • Reference Examples A, B and C demonstrate significant cytotoxicity (ratio of Cell Tox EC50 to USP30 IC50) compared to Examples 1, 4, 6 and 8.
  • Reference Examples A and B demonstrate significant cytotoxicity compared to Examples 2, 3, 5 and 7.
  • UUO causes renal injury characterised by tubular cell injury, interstitial inflammation and fibrosis. It serves as a model of irreversible post-renal acute kidney injury (AKI).
  • AKI irreversible post-renal acute kidney injury
  • Experimental UUO has illustrated the molecular mechanisms of apoptosis, inflammation and fibrosis, all of which are key processes in renal injury, regardless of the primary insult. Consequently, the UUO model provides investigators information beyond obstruction (Chevalier et al, 2009, Kidney Int 75(11): 1145-1152).
  • Example 1 was assessed in the UUO model to determine the ability of the compound to attenuate progressive tubulointerstitial fibrosis and chronic kidney disease (CKD).
  • CKD chronic kidney disease
  • Example 1 results demonstrated that 15 mg/kg Example 1 (p.o.) dosed either QD or BID, statistically reduced collagen deposition as evidenced by reduced picrosirius red staining in ligated kidneys.
  • Assessment of a-SMA staining revealed that oral dosing of 15 mg/kg Example 1 QD or BID resulted in a non- statistical reduction in a-SMA levels in UUO injured kidneys when compared to vehicle treated controls.
  • AKI can be induced by bilateral renal pedical clamping resulting in ischemia reperfusion injury (IRI) resulting in severe loss of renal function tubular damage and inflammation.
  • IRI ischemia reperfusion injury
  • Example 1 was administered to C57BL/6 mice 15 mg/kg (p.o.) and compared to vehicle treatment from Day -1 through to Day +21. On Day 0, mice were anaesthetized, and their left renal pedicle clamped for 45 min, then released to induce IRI. Mice were monitored and urinary kidney injury biomarkers (KIM-1 and NGAL) were measured on Day +1 and +7. On Day +14 and Day +21 kidneys were harvested. Morphology, fibrosis and immune cell infiltration were assessed.
  • KIM-1 and NGAL urinary kidney injury biomarkers
  • Example 1 Body weight was similar between groups and remained constant throughout the observation periods.
  • Example 1 appeared to limit urinary kidney injury biomarkers, KIM1 and NGAL on Day +1. There were large interindividual variations and the differences did not reach significance. Macrophage infiltration was significantly reduced on Day +21. Masson trichome stain revealed significantly less tubular atrophy in Example 1 treated animals on Day +14 and Day +21. Fibronectin expression in the cortex was significantly reduced in Example 1 treated mice on Day +14 and +21.
  • Example 1 demonstrated efficacy in this model of IR-induced CKD. Daily treatment has shown significant benefits towards attenuated tubular atrophy and reduced cortical fibrosis.
  • mice On Day 0 (zero) C57BL/6 mice were anaesthetized, and their left renal pedicle clamped for 45 min, then released to induce IRI. Mice were then administered either vehicle or Example 115 mg/kg (p.o.) BID for 21 days, with first treatment starting five hours following IRI surgery (i.e. therapeutics dosing). Mice were monitored and kidneys harvested at Day +21. Kidney sections were quantitatively assessed for relative cellular morphology, fibrosis and macrophage infiltration using blinded histological scoring methods.
  • Example 1 treated mice Body weight was similar between groups and remained constant throughout the observation periods. Masson trichrome staining revealed significantly less tubular atrophy in Example 1 treated animals on Day +21. Similarly, fibronectin expression and macrophage infiltration in the cortex was also significantly reduced in Example 1 treated mice on Day +21.
  • Example 1 demonstrated efficacy in this model of IR-induced CKD when dosed therapeutically. Initiating treatment after the establishment of ischemia-reperfusion injury has shown significant benefits towards attenuated tubular atrophy and reduced cortical fibrosis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (I).

Description

SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS FIELD OF THE INVENTION
The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme ubiquitin C-terminal hydrolase 30, also known as ubiquitin specific peptidase 30 (USP30), uses thereof, processes for the preparation thereof and composition containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis.
All documents cited or relied upon below are expressly incorporated herein by reference.
BACKGROUND OF THE INVENTION
Ubiquitin is a small protein consisting of 76 amino acids that is important for the regulation of protein function in the cell. Ubiquitylation and deubiquitylation are enzymatically mediated processes by which ubiquitin is covalently bound or cleaved from a target protein by deubiquitylating enzymes (DUBs), of which there are approximately 100 DUBs in human cells, divided into sub-families based on sequence homology. The USP family are characterised by their common Cys and His boxes which contain Cys and His residues critical for their DUB activities. The ubiquitylation and deubiquitylation processes have been implicated in the regulation of many cellular functions including cell cycle progression, apoptosis, modification of cell surface receptors, regulation of DNA transcription and DNA repair. Thus, the ubiquitin system has been implicated in the pathogenesis of numerous disease states including inflammation, viral infection, metabolic dysfunction, CNS disorders, and oncogenesis.
Ubiquitin is a master regulator of mitochondrial dynamics. Mitochondria are dynamic organelles whose biogenesis, fusion and fission events are regulated by the post-translational regulation via ubiquitylation of many key factors such as mitofusins. In humans, USP30 is a 517 amino acid protein which is found in the mitochondrial outer membrane (Nakamura et al, 2008, Mol Biol 19:1903-11). It is the sole deubiquitylating enzyme bearing a mitochondrial addressing signal and has been shown to deubiquitylate a number of mitochondrial proteins. It has been demonstrated that USP30 opposes parkin-mediated mitophagy and that reduction of USP30 activity can rescue parkin-mediated defects in mitophagy (Bingol et al, 2015, Nature 510:370-5; Gersch et al, 2017, Nat Struct Mol Biol 24(11): 920-930; Cunningham et al, 2015, Nat Cell Biol 17(2): 160-169). USP30 inactivation can also increase mitochondrial protein import, potentially through ubiquitylation of TOM proteins (Jacoupy et al, 2019, Sci Rep 9(1): 11829). A small proportion of USP30 has been localized to peroxisomes, which are generated through fusion of mitochondrial and ER vesicles, with USP30 potentially antagonizing the Pex2/pexophagy pathway (Riccio et al, 2019, J Cell Biol 218(3): 798-807). The E3 Ub ligase March5 and the deubiquitinase USP30 associate with the translocase and regulate mitochondrial import, and while March5 opposes mitochondrial import and directs degradation of substrates, USP30 deubiquitinates substrates to promote their import (Phu et al, 2020, Molecular Cell 77, 1107-1123).
Mitochondrial dysfunction can be defined as diminished mitochondrial content (mitophagy or mitochondrial biogenesis), as a decrease in mitochondrial activity and oxidative phosphorylation, but also as modulation of reactive oxygen species (ROS) generation. Hence a role for mitochondrial dysfunctions in a very large number of aging processes and pathologies.
For example, Parkinson’s disease affects around 10 million people worldwide (Parkinson’s Disease Foundation) and is characterised by the loss of dopaminergic neurons in the substantia nigra. The exact mechanisms underlying PD are unclear; however mitochondrial dysfunction is increasingly appreciated as a key determinant of dopaminergic neuronal susceptibility in PD and is a feature of both familial and sporadic disease, as well as in toxin-induced Parkinsonism. Parkin is one of a number of proteins that have been implicated with early onset PD. While most PD cases are linked to defects in alpha-synuclein, 10% of Parkinson’s cases are linked to specific genetic defects, one of which is in the ubiquitin E3 ligase parkin. Parkin and the protein kinase PTEN-induced putative kinase 1 (PINK1) collaborate to ubiquitylate mitochondrial membrane proteins of damaged mitochondria resulting in mitophagy. Dysregulation of mitophagy results in increased oxidative stress, which has been described as a characteristic of PD. Inhibition of USP30 could therefore be a potential strategy for the treatment of PD. For example, PD patients with parkin mutations leading to reduced activity could be therapeutically compensated by inhibition of USP30.
It has been reported that depletion of USP30 enhances mitophagic clearance of mitochondria and also enhances parkin-induced cell death. USP30 has also been shown to regulate BAX/BAK-dependent apoptosis independently of parkin overexpression. Depletion of USP30 sensitises cancer cells to BH- 3 mimetics such as ABT-737, without the need for parkin overexpression. Thus, an anti-apoptotic role has been demonstrated for USP30 and USP30 is therefore a potential target for anti-cancer therapy.
The ubiquitin-proteasome system has gained interest as a target for the treatment of cancer following the approval of the proteasome inhibitor bortezomib (Velcade®) for the treatment of multiple myeloma. Extended treatment with bortezomib is limited by its associated toxicity and drug resistance. However, therapeutic strategies that target specific aspects of the ubiquitin-proteasome pathway upstream of the proteasome, such as DUBs, are predicted to be better tolerated (Bedford et al, 2011, Nature Rev 10:29-46).
Fibrotic diseases, including renal, hepatic and pulmonary fibrosis, are a leading cause of morbidity and mortality and can affect all tissues and organ systems. Fibrosis is considered to be the result of acute or chronic stress on the tissue or organ, characterized by extracellular matrix deposition, reduction of vascular/tubule/duct/airway patency and impairment of function ultimately resulting in organ failure. Many fibrotic conditions are promoted by lifestyle or environmental factors; however, a proportion of fibrotic conditions can be initiated through genetic triggers or indeed are considered idiopathic (i.e. without a known cause). Certain fibrotic disease, such as idiopathic pulmonary fibrosis (IPF), can be treated with non-specific kinase inhibitor (nintedanib) or drugs without a well- characterized mechanism of action (pirfenidone). Other treatments for organ fibrosis, such as kidney or liver fibrosis, alleviate pressure on the organ itself (e.g. beta blockers for cirrhosis, angiotensin receptor blockers for chronic kidney disease). Attention to lifestyle factors, such as glucose and diet control, may also influence the course and severity of disease.
Mitochondrial dysfunction has been implicated in a number of fibrotic diseases, with oxidative stress downstream of dysfunction being the key pathogenic mediator, alongside decreased ATP production. In preclinical models, disruption of the mitophagy pathway (through mutation or knockout of either parkin or PINK1) exacerbates lung fibrosis and kidney fibrosis, with evidence of increased oxidative stress.
Kurita et al, 2017, Respiratory Research 18:114, discloses that accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodelling in IPF. Recent findings are said to show participation of autophagy/mitophagy, part of the lysosomal degradation machinery, in IPF pathogenesis, and that mitophagy has been implicated in myofibroblast differentiation through regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-derived growth factor receptor (PDGFR) activation. Kurita’s results suggested that pirfenidone induces PARK2-mediated mitophagy and also inhibits lung fibrosis development in the setting of insufficient mitophagy, which may at least partly explain the anti-fibrotic mechanisms for IPF treatment.
Williams et al, 2015, Pharmacol Res. December; 102: 264-269, discuss the role of PINK1-Parkin- mediated autophagy in protecting against alcohol and acetaminophen-induced liver injury by removing damaged mitochondria via mitophagy. It is suggested that pharmacological stabilization of USP8 or inactivation of USP15 and USP30 may be potential therapeutic targets for upregulating Parkin-induced mitophagy and in turn protect against drug-induced liver injury. However, it is noted that the DUBs are regulated both transcriptionally and post-translationally, which may make drug development for targeting these specific enzymes challenging, and in addition, phosphorylated ubiquitin was shown to be resistant to DUBs. The authors conclude that upregulating PINK1 stabilization or kinase activity may be a more effective target than inhibiting DUBs.
Williams et al, 2015, Biomolecules 5, 2619-2642, and Williams et al, 2015, Am J Physiol Gastrointest Liver Physiol 309: G324–G340, review mechanisms involved in regulation of mitochondrial homeostasis in the liver and how these mechanisms may protect against alcohol-induced liver disease. Series of derivatives of cyano-substituted heterocycles are disclosed as deubiquitylating enzyme inhibitors in PCT applications WO 2016/046530 (US 15/513125, US 15/894025, US 16/448066), WO 2016/156816 (US 15/558632, US 16/297937, US 16/419558, US 16/419747, US 16/788446), WO 2017/009650 (US 15/738900), WO 2017/093718 (US 15/776149), WO 2017/103614 (US 15/781615), WO 2017/149313 (US 16/078518), WO 2017/109488 (US 16/060299), WO 2017/141036 (US 16/070936), WO 2017/163078 (US 16/087515), WO 2017/158381 (US 16/080229), WO 2017/158388 (US 16/080506), WO 2018/065768 (US 16/336685), WO 2018/060742 (US 16/336202), WO 2018/060689 (US 16/334836), WO 2018/060691 (US 16/336363), WO 2018/220355 (US 16/615040), and WO 2018/234755 (US 16/615709), each of which are expressly incorporated herein by reference. PCT application WO 2019/171042, which is expressly incorporated herein by reference, discloses the use of substituted-cyanopyrrolidines as inhibitors of USP30 for the treatment of fibrotic diseases.
Falgueyret et al, 2001, J.Med.Chem. 44, 94-104, and PCT application WO 01/77073 refer to cyanopyrrolidines as inhibitors of Cathepsins K and L, with potential utility in treating osteoporosis and other bone-resorption related conditions. PCT application WO 2015/179190 refers to N-acylethanolamine hydrolysing acid amidase inhibitors, with potential utility in treating ulcerative colitis and Crohn’s disease. PCT application WO 2013/030218 refers to quinazolin-4-one compounds as inhibitors of ubiquitin specific proteases, such as USP7, with potential utility in treating cancer, neurodegenerative diseases, inflammatory disorders and viral infections. PCT applications WO 2015/017502 and WO 2016/019237 refer to inhibitors of Bruton’s tyrosine kinase with potential utility in treating disease such as autoimmune disease, inflammatory disease and cancer. PCT applications WO 2009/026197, WO 2009/129365, WO 2009/129370, and WO 2009/129371, refer to cyanopyrrolidines as inhibitors of Cathepsin C with potential utility in treating COPD. United States patent application US 2008/0300268 refers to polyaromatic compounds as inhibitors of tyrosine kinase receptor PDGFR. PCT applications WO 2019/222468 and WO 2019/071073 refer to cyanamide-containing compounds as USP30 inhibitors.
PCT application WO 2015/183987, refers to pharmaceutical compositions comprising deubiquitinase inhibitors and human serum albumin in methods of treating cancer, fibrosis, an autoimmune disease or condition, an inflammatory disease or condition, a neurodegenerative disease or condition or an infection. It is noted that deubiquitinases, including UCHL5/UCH37, USP4, USP9X, USP11 and USP15, are said to have been implicated in the regulation of the TGF-beta signalling pathway, the disruption of which gives rise to neurodegenerative and fibrotic diseases, autoimmune dysfunction and cancer.
PCT application WO 2006/067165 refers to a method for treating fibrotic diseases using indolinone kinase inhibitors. PCT application WO 2007/119214 refers to a method for treating early stage pulmonary fibrosis using an endothelin receptor antagonist. PCT application WO 2012/170290 refers to a method for treating fibrotic diseases using THC acids. PCT application WO 2018/213150 refers to sulfonamide USP30 inhibitors with potential utility in the treatment of conditions involving mitochondrial defects. Larson-Casey et al, 2016, Immunity 44, 582-596, concerns macrophage Akt1 kinase-mediated mitophagy, apoptosis resistance and pulmonary fibrosis. Tang et al, 2015, Kidney Diseases 1, 71-79, reviews the potential role of mitophagy in renal pathophysiology.
There exists a need for safe, alternative, and/or improved methods and compositions for the treatment or prevention of conditions involving mitochondrial dysfunction, cancer and fibrosis, and the various symptoms and conditions associated therewith. While not wishing to be bound by any particular theory or mechanism, it is believed that the compounds of the present invention act to inhibit the enzyme USP30, which in turn upregulates Parkin-induced mitophagy.
Acute Kidney Injury (AKI) is defined as an abrupt decrease in kidney function occurring over 7 days or less, with severity of injury staged based on increased serum creatinine (SCr) and decreased urine output as described in the Kidney Disease Improving Global Outcomes (KDIGO) guidelines. AKI occurs in about 13.3 million people per year, 85% of whom live in the developing world and it is thought to contribute to about 1.7 million deaths every year (Mehta et al, 2015, Lancet 385(9987): 2616-2643). AKI more than likely results in permanent kidney damage (i.e., chronic kidney disease; CKD) and may also result in damage to non-renal organs. AKI is a significant public health concern particularly when considering the absolute number of patients developing incident CKD, progressive CKD, end-stage renal disease and cardiovascular events.
AKI and CKD are viewed as a continuum on the same disease spectrum (Chawla et al, 2017, Nat Rev Nephrol 13(4): 241-257). Patients undergoing coronary artery bypass graft (CABG) are at high risk for kidney injury. There is an obvious unmet medical need in the development of medicinal products for the treatment and/or prevention of AKI.
The kidney is a site of high metabolic demand, with high mitophagy rates demonstrated in vivo (McWilliams et al, 2018, Cell Metab 27(2): 439-449 e435). Renal Proximal Tubule Epithelial Cells (RPTECs), a cell type with significant ATP requirement for solute/ion exchange, are rich in mitochondria and are the primary effector cells of Acute Kidney Injury (AKI) in the kidney. Mitochondrial dysfunction has been implicated in AKI/CKD mechanisms, both through multiple lines of evidence from preclinical AKI and CKD models and also through data demonstrating abnormal mitochondrial phenotypes in patient biopsies (Emma et al, 2016, Nat Rev Nephrol 12(5): 267-280; Eirin et al, 2017, Handb Exp Pharmacol 240: 229-250). Furthermore, Primary mitochondrial disease often manifest in renal symptoms, such as focal segmental glomerulosclerosis (Kawakami et al, 2015, J Am Soc Nephrol 26(5): 1040-1052) in patients with MELAS/MIDD, and also primary tubular pathologies in patients with Coenzyme Q deficiencies. Mutations in mtDNA can cause maternally inherited tubulointerstitial disease (Connor et al, 2017, PLoS Genet 13(3): e1006620).
Regarding mitochondrial quality control in renal injury (Tang et al, 2018, Autophagy 14(5): 880-897) demonstrated that renal injury was exacerbated following ischemic AKI in both PINK1 KO and PARK2 KO mice, suggesting that PINK1/PARKIN-mediated mitophagy plays a protective role following IRI in the kidney. In addition, parkin/PINK1 mitophagy protects against cisplatin induced kidney injury (Wang et al, 2018, Cell Death Dis 9(11): 1113). Limited models of CKD are available for mitophagy investigation, supportive evidence for mitochondrial quality control in fibrosis comes from studies on fibrotic lung conditions such as COPD and IPF. Parkin knockout animals show exacerbated lung fibrosis in response to bleomycin (Kobayashi et al, 2016, J Immunol, 197:504-516). Similarly, airway epithelial cells from parkin knockout (KO) animals show exacerbated fibrotic and senescent responses to cigarette smoke (Araya et al, 2019, Autophagy 15(3): 510-526).
Preclinical models are available to study potential novel therapeutics, through their ability to model fibrosis pathology (e.g. collagen deposition) consistent with the human condition. Preclinical models can be toxin-mediated (e.g. bleomycin for lung and skin fibrosis), surgical (e.g. ischemia/reperfusion injury model and unilateral ureter obstruction model for acute tubulointerstitial fibrosis), and genetic (e.g. diabetic (db/db) mice for diabetic nephropathy). For example, both examples previously given for indicated IPF treatments (nintedanib and pirfenidone) show efficacy in the bleomycin lung fibrosis model.
Accordingly, there is a need for compounds that are inhibitors of USP30 for the treatment or prevention of conditions where inhibition of USP30 is indicated. In particular, there exists a need for USP30 inhibitors that have suitable and/or improved properties in order to maximise efficacy against the target disease.
SUMMARY OF THE INVENTION
The present invention is directed to compounds of formula (I):
Figure imgf000007_0001
a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein: R1 is selected from (C1-C4)alkyl, (C1-C4)fluoroalkyl, CH2OCH3 and CH2N(CH3)2;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine. The present invention is also directed to uses of the compounds of formula (I), particularly in the treatment of conditions involving mitochondrial dysfunction, cancer and fibrosis, and also processes for the preparation thereof and pharmaceutical compositions containing said compounds.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to USP30 inhibitors that have suitable and/or improved properties in order to maximise efficacy against the target disease. Such properties include, for example, potency, selectivity, physicochemical properties, ADME (absorption, distribution, metabolism and excretion) properties, including PK (pharmacokinetic) profile, and safety profile.
It is generally desirable to maximise the potency of a drug molecule against the target enzyme in relevant assays in order to lower the effective/efficacious dosage that is to be administered to patients. Compounds of the invention may be tested for USP30 affinity using the in vitro biochemical fluorescence polarization (FP) assay described herein.
USP30 is a transmembrane protein located in the outer membrane of mitochondria, which are energy- producing organelles present inside cells. Therefore, being able to demonstrate cellular activity in vitro is advantageous, as this is one of a number of components that may indicate a greater ability to engage the target in its physiological setting, i.e. where the USP30 inhibitor compound is able to penetrate cells. The USP30 cellular western blot (WB) assay described herein aims to test the activity of compounds against USP30 in cells using an irreversible activity probe to monitor USP30 activity. Analogously to the cellular western blot assay, target engagement assessment (ex vivo) may be carried out in either brain or kidney tissue samples from compound-dosed animals using the assay described herein.
To extend target binding knowledge to downstream pharmacodynamics, assessment of TOM20 (an outer mitochondrial membrane protein) ubiquitylation may be made.
In general, it is important for a drug to be as selective as possible for its desired target enzyme; additional activities give rise to the possibility of side effects. The exact physiological role of many DUBs has yet to be fully determined, however, irrespective of whatever role these DUBs may or may not play, it is a sound medicinal chemistry precept to ensure that any drug has selectivity over related mechanistic targets of unknown physiological function. Representative examples of DUB enzymes for which the compounds of the present invention may be screened against are UCHL1, UCHL3, UCHL5, YOD1, SENP2, SENP6, TRABID, BAP1, Cezanne, MINDY2/FAM63B, OTU1, OTUD3, OTUD5, OTUD6A, OTUD6B, OTUB1/UBCH5B, OTUB2, CYLD, VCPIP, AMSH-LP, JOSD1, JOSD2, USP1/UAF1, USP2, USP4, USP5, USP6, USP7, USP8, USP9x, USP10, USP11, USP12/UAF1, USP13, USP14, USP15, USP16, USP19, USP20, USP21, USP22, USP24, USP25, USP28, USP32, USP34, USP35, USP36, USP45, USP46/UAF1, USP47 and USP48. Preferably, compounds of the invention have good selectivity for USP30 over one or more of these DUB enzymes.
Aside from selectivity over other DUB enzymes, it is important for a drug to have low affinity for other targets, and pharmacological profiling may be performed against panels of targets to assess the potential for, and to minimise, potential off-target effects. Examples of targets for which the compounds of the present invention may be screened against are those of the industry standard Eurofins-Cerep SafetyScreen44 panel, which includes 44 targets as a representative selection of GPCR receptors, transporters, ion channels, nuclear receptors, and kinase and non-kinase enzymes. Preferably, compounds of the invention have insignificant affinity against targets of this screening panel. Further examples of targets for which the compounds of the present invention may be screened against are kinases of the Thermo Fisher SelectScreen kinase profiling panel, which includes 39 targets as a representative selection of kinase enzymes. Preferably, compounds of the invention have insignificant affinity against targets of this screening panel. Additionally, examples of a particular enzyme class for which the compounds of the present invention may be screened against are the cathepsins (e.g. cathepsin A, B, C, H, K, L, L2, S, V and Z). Preferably, compounds of the invention have good selectivity for USP30 over one or more of these enzymes.
There is also a need for compounds that have favourable pharmacokinetic properties such that they are suitable for oral administration. An orally administered drug should have good bioavailability; that is an ability to readily cross the gastrointestinal (GI) tract and not be subject to extensive metabolism as it passes from the GI tract into the systemic circulation. Once a drug is in the systemic circulation the rate of metabolism is also important in determining the time of residence of the drug in the body.
Thus, it is clearly favourable for drug molecules to have the properties of being readily able to cross the GI tract and being only slowly metabolised in the body. The Caco-2 assay is a widely accepted model for predicting the ability of a given molecule to cross the GI tract. The majority of metabolism of drug molecules generally occurs in the liver, and in vitro assays using whole cell hepatocytes (animal or human) are widely accepted methods for measuring the susceptibility of a given molecule towards metabolism in the liver. Such assays aim to predict in vivo clearance from the hepatocyte calculated clearance value.
Compounds which have good Caco-2 flux and are stable towards hepatocytes are predicted to have good oral bioavailability (good absorption across the GI tract and minimal extraction of compound as it passes through the liver) and a long residence time in the body that is sufficient for the drug to be efficacious.
The solubility of a compound is an important factor in achieving a desired concentration of drug in systemic circulation for the anticipated pharmacological response. Low aqueous solubility is a problem encountered with formulation development of new chemical entities and to be absorbed a drug must be present in the form of solution at the site of absorption. The kinetic solubility of a compound may be measured using a turbidimetric solubility assay, the data from which may also be used in conjunction with Caco-2 permeability data to predict dose dependent human intestinal absorption.
Other parameters that may be measured using standard assays that are indicative of a compound’s exposure profile include, for example plasma stability (half-life measurement), blood AUC, Cmax, Cmin and Tmax values.
The treatment of CNS disorders, including Alzheimer’s disease, Parkinson’s disease, and other disorders described herein, requires drug molecules to target the brain, which requires adequate penetration of the blood brain barrier. There is, therefore, a need for USP30 inhibitors that possess effective blood brain penetration properties and provide suitable residence time in the brain to be efficacious. The probability that a compound can cross the blood brain barrier may be measured by an in vitro flux assay utilizing a MDR1-MDCK cell monolayer (Madin-Darby Canine Kidney cells transfected with MDR-1 resulting in overexpression of the human efflux transporter P-glycoprotein). Additionally, exposure may also be measured directly in brain and plasma using in vivo animal models.
There is also a need for compounds that have a favourable safety profile, which may be measured by a variety of standard in vitro and in vivo methods. A cell toxicity counter-screen may be used to assay the anti-proliferative/cytotoxic effect in a particular cell line (e.g. HCT116) by fluorometric detection of rezasurin (alamarBlue) to resofurin in response to mitochondrial activity.
Toxicology and safety studies may also be conducted to identify potential target organs for adverse effects and define the Therapeutic Index to set the initial starting doses in clinical trials. Regulatory requirements generally require studies to be conducted in at least two laboratory animal species, one rodent (rat or mouse) and one nonrodent (rabbit, dog, non-human primate, or other suitable species). The bacterial reverse mutation assay (Ames Test) may be used to evaluate the mutagenic properties of compounds of the invention, commonly by using the bacterial strain Salmonella typhimurium, which is mutant for the biosynthesis of the amino acid histidine.
The micronucleus assay may be used to determine if a compound is genotoxic by evaluating the presence of micronuclei. Micronuclei may contain chromosome fragments produced from DNA breakage (clastogens) or whole chromosomes produced by disruption of the mitotic apparatus (aneugens).
The hERG predictor assay provides valuable information about the possible binding of test compounds to the potassium channel and potential QT prolongation on echocardiogram. Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia (Torsades de Pointes). Typically, assay data may be generated from an automated patch-clamp assay platform.
The present invention is therefore directed to USP30 inhibitors that have suitable and/or improved properties in order to maximise efficacy against the target disease. Such properties include, for example, potency, selectivity, physicochemical properties, ADME (absorption, distribution, metabolism and excretion) properties, including PK (pharmacokinetic) profile, and safety profile. The compounds of the present invention have been found to demonstrate one or more of the above identified advantages over reference examples from the prior art sharing some structural similarity that are both significant and unexpected. For instance, all of the Examples of the present invention are significantly more potent for USP30 than the Reference Examples as measured in the biochemical assay described herein. All of the Examples of the present invention are significantly more selective for USP30 over other DUBs.
The significant and unexpected superiority of the compounds of the present invention make them particularly suitable for use in the treatment and/or prevention of diseases linked to UP30 activity. According to a first aspect, the present invention provides a compound of formula (I):
Figure imgf000011_0001
a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein: R1 is selected from (C1-C4)alkyl, (C1-C4)fluoroalkyl, CH2OCH3 and CH2N(CH3)2;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
The compound of formula (I) exists as a single stereoisomer with the absolute stereochemistry shown. Alkyl groups may be straight or branched and contain 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and sec-butyl.
Fluoroalkyl groups may contain one or more fluorine substituents. Examples are fluoromethyl, difluoromethyl and trifluoromethyl. Unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be selected from more than one alternative, the selected groups may be the same or different. The term‘independently’ means that where more than one substituent is selected from more than one possible substituent, those substituents may be the same or different.
Preferred embodiments of the compound of formula (I) for use in the present invention are defined below.
Preferably, R1 is selected from methyl, CH2F, CHF2, CF3, CH2OCH3 and CH2N(CH3)2.
More preferably, R1 is selected from methyl and CH2OCH3.
In one preferred embodiment, R1 is methyl.
In another preferred embodiment, R1 is CH2OCH3.
Preferably, R2 is hydrogen.
Preferably, R3 is hydrogen.
Preferably, R4 is selected from hydrogen and fluorine.
Most preferably, R4 is hydrogen.
Preferably, R5 is selected from hydrogen and fluorine.
Most preferably, R5 is hydrogen.
Preferably, R6 is hydrogen.
According to one preferred embodiment of the invention:
R1 is selected from methyl and CH2OCH3;
R2 is hydrogen;
R3 is hydrogen;
R4 is selected from hydrogen and fluorine;
R5 is selected from hydrogen and fluorine; and
R6 is hydrogen.
According to one preferred aspect of the invention:
R1 is (C1-C4)alkyl;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
Preferably, R1 is methyl;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
More preferably, R1 is methyl;
R2 is hydrogen; and R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
Yet more preferably, R1 is methyl;
R2 is hydrogen;
R3 is hydrogen;
R4 is selected from hydrogen and fluorine;
R5 is selected from hydrogen and fluorine; and
R6 is hydrogen.
According to another preferred aspect of the invention:
R1 is CH2OCH3;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
Preferably, R1 is CH2OCH3;
R2 is hydrogen; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
Yet more preferably, R1 is CH2OCH3;
R2 is hydrogen;
R3 is hydrogen;
R4 is selected from hydrogen and fluorine;
R5 is selected from hydrogen and fluorine; and
R6 is hydrogen.
Preferred compounds of formula (I) for use in the present invention are selected from:
N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide;
5-(3-cyano-5-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide; N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)-4-methyloxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(fluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(difluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((dimethylamino)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; and
5-(3-cyano-4-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide; a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.
Most preferred compounds of formula (I) for use in the present invention are selected from:
N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; and N-((3R,5S)-1-cyano-5-(methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer. Pharmaceutical acceptable salts of the compounds of formula (I) include the acid addition and base salts (including di-salts) thereof.
Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate, camsylate, citrate, edisylate, esylate, fumarate, gluceptate, gluconate, glucuronate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, hydrogen phosphate, isethionate, D- and L-lactate, malate, maleate, malonate, mesylate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, palmate, phosphate, saccharate, stearate, succinate sulfate, D-and L-tartrate, and tosylate salts.
Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, ammonium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
For a review on suitable salts, see Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, Germany (2002).
A pharmaceutical acceptable salt of a compound of formula (I) may be readily prepared by mixing together solutions of the compound of formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
Pharmaceutical acceptable solvates in accordance with the invention include hydrates and solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, acetone-d6, DMSO-d6. Also, within the scope of the invention are clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in non-stoichiometric amounts. For a review of such complexes, see J. Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975). Hereinafter all references to compounds of formula (I) include references to salts thereof and to solvates and clathrates of compounds of formula (I) and salts thereof.
The invention includes all polymorphs of the compounds of formula (I) as hereinbefore defined. Also, within the scope of the invention are so-called "prodrugs" of the compounds of formula (I). Thus, certain derivatives of compounds of formula (I) which have little or no pharmacological activity themselves can, when metabolised upon administration into or onto the body, give rise to compounds of formula (I) having the desired activity. Such derivatives are referred to as "prodrugs".
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as "pro-moieties" as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985).
Finally, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I).
Certain derivatives of compounds of formula (I) which contain a nitrogen atom may also form the corresponding N-oxide, and such compounds are also within the scope of the present invention.
Included within the scope of the present invention are all tautomeric forms of the compounds of formula (I).
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high performance liquid chromatography (HPLC). Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture. The present invention includes all crystal forms of the compounds of formula (I) including racemates and racemic mixtures (conglomerates) thereof. Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994). The compounds of formula (I) contain two chiral centres at the carbon atoms of the pyrrolidine ring that are substituted by R1 and the amide and said stereocentres could exist in either the (R) or (S) configuration. The designation of the absolute configuration (R) and (S) for stereoisomers in accordance with IUPAC nomenclature is dependent on the nature of the substituents and application of the sequence-rule procedure. The compounds of formula (I) could, therefore, exist in four stereoisomeric forms.
The compounds of formula (I) of the present invention exist as a single stereoisomer. The pyrrolidine carbon atom of the amide substituent exists as the (R)-stereocentre, whereas the designation of the pyrrolidine carbon atom of the R1 group is dependent on the nature of the substituent. The compound of formula (I) is isolated as a single stereoisomer and may exist with a stereoisomeric excess of at least 60%, preferably at least 80%, more preferably at least 90%, more preferably at least 95%, for example 96%, 97%, 98%, 99%, or 100%.
Additional chiral centres may exist in the compounds of formula (I) within the R1 substituent itself. Included within the scope of the present invention are all such stereoisomeric forms of the compounds of formula (I).
The present invention also includes all pharmaceutically acceptable isotopic variations of a compound of formula (I). An isotopic variation is defined as one in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature.
Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 13C and 14C, nitrogen, such as 15N, oxygen, such as 17O and 18O, phosphorus, such as 32P, sulfur, such as 35S, fluorine, such as 18F, and chlorine, such as 36CI. Substitution of the compounds of the invention with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half- life or reduced dosage requirements, and hence may be preferred in some circumstances.
Certain isotopic variations of the compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, and 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
Isotopic variations of the compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using appropriate isotopic variations of suitable reagents. The compounds of formula (I) are inhibitors of the deubiquitylating enzyme USP30.
According to a further aspect, the present invention provides a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer for use as a medicament.
According to a further aspect, the present invention provides a method of treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect, in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.
According to a further aspect, the present invention provides the use of a compound of formula (I) as defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for the treatment or prevention of a disorder or condition where inhibition of USP30 is known, or can be shown, to produce a beneficial effect. The manufacture of a medicament may include, inter alia, the chemical synthesis of the compound of formula (I) or a salt thereof, or the preparation of a composition or formulation comprising the compound or salt, or the packaging of any medicament comprising the compound.
The disorder or condition benefiting from USP30 activity is selected from a condition involving mitochondrial dysfunction, cancer and fibrosis.
In one preferred embodiment of all aspects of the invention, the disorder or condition benefiting from USP30 activity is a condition involving mitochondrial dysfunction.
Mitochondrial dysfunctions result from defects of the mitochondria, which are specialized compartments present in every cell of the body except red blood cells. When mitochondria fail, less and less energy is generated within the cell and cell injury or even cell death will follow. If this process is repeated throughout the body the life of the subject in whom this is happening is severely compromised. Diseases of the mitochondria appear most often in organs that are very energy demanding such as the brain, heart, liver, skeletal muscles, kidney and the endocrine and respiratory system.
The condition involving mitochondrial dysfunction may be selected from a condition involving a mitophagy defect, a condition involving a mutation in mitochondrial DNA, a condition involving mitochondrial oxidative stress, a condition involving a defect in mitochondrial membrane potential, mitochondrial biogenesis, a condition involving a defect in mitochondrial shape or morphology, and a condition involving a lysosomal storage defect.
In particular, the condition involving mitochondrial dysfunction may be selected from a neurodegenerative disease; multiple sclerosis (MS); mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome; materially-inherited diabetes and deafness (MIDD); Leber's hereditary optic neuropathy (LHON); cancer (including, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, and non-small cell lung carcinoma); neuropathy, ataxia, retinitis pigmentosa, maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric diseases, for example schizophrenia; multiple sulfatase deficiency (MSD); mucolipidosis II (ML II); mucolipidosis III (ML III); mucolipidosis IV (ML IV); GMl-gangliosidosis (GM1); neuronal ceroid- lipofuscinoses (NCL1); Alpers disease; Barth syndrome; beta-oxidation defects; carnitine-acyl- carnitine deficiency; carnitine deficiency; creatine deficiency syndromes; co-enzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex III deficiency; complex IV deficiency; complex V deficiency; COX deficiency; chronic progressive external ophthalmoplegia syndrome (CPEO); CPT I deficiency; CPT II deficiency; glutaric aciduria type II; Kearns-Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency (LCHAD); Leigh disease or syndrome; Leigh Syndrome French Canadian (LSFC) variant; lethal infantile cardiomyopathy (LIC); Luft disease; glutaric aciduria type II; medium-chain acyl-CoA dehydrogenase deficiency (MCAD); myoclonic epilepsy and ragged-red fiber (MERRF) syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastointestinal disorder and encephalopathy; Pearson syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG mutations; medium/short-chain 3-hydroxyacyl- CoA dehydrogenase (M/SCHAD) deficiency; very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency; peroxisomal disorders; methylmalonic acidemia; and age-dependent decline in cognitive function and muscle strength.
The condition involving mitochondrial dysfunction may be a CNS disorder, for example a neurodegenerative disease.
Neurodegenerative diseases include, but are not limited to, Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia.
In particular, the compounds of the invention may be useful in the treatment or prevention of Parkinson’s disease, including, but not limited to, PD related to mutations in a-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease (AR-JP) where parkin is mutated.
The compounds of the invention or pharmaceutical compositions thereof as described herein may be combined with one or more additional agents when used for the treatment or prevention of conditions involving mitochondrial dysfunction. The compounds may be combined with one or more additional agents selected from levodopa, a dopamine agonist, a monoamino oxygenase (MAO) B inhibitor, a catechol O-methyltransferase (COMT) inhibitor, an anticholinergic, riluzole, amantadine, a cholinesterase inhibitor, memantine, tetrabenazine, an antipsychotic, diazepam, clonazepam, an antidepressant, and an anti-convulsant. The compounds may be combined with agents which reduce/remove pathogenic protein aggregates in neurodegenerative diseases, such as agents which reduce/remove alpha-synuclein in Parkinson’s disease, multiple system atrophy or dementia with Lewy bodies; agents which reduce/remove Tau in Alzheimer’s disease or progressive supranuclear palsy; agents which reduce/remove TDP-43 in ALS or frontotemporal dementia. In another preferred embodiment of all aspects of the invention, the disorder or condition benefiting from USP30 activity is cancer. The cancer may be linked to mitochondrial dysfunction. Preferred cancers include, for example, breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and cancers of the blood cells, such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, and non-small cell lung carcinoma.
In particular, the compounds of the invention may be useful in the treatment or prevention of cancer where apoptotic pathways are dysregulated and more particularly where proteins of the BCL-2 family are mutated, or over or under expressed.
Fibrosis refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Fibrotic disorders that may be treated by the compounds and compositions of the present invention include, inter alia, fibrosis/fibrotic disorders associated with major organ diseases, for example, interstitial lung disease (ILD), liver cirrhosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (hepatic fibrosis), kidney disease (renal fibrosis), acute kidney injury (AKI), chronic kidney disease (CKD), delayed kidney graft function, heart or vascular disease (cardiac fibrosis) and diseases of the eye; fibroproliferative disorders, for example, systemic and local scleroderma, keloids and hypertrophic scars, atherosclerosis, restenosis, and Dupuytren’s contracture; scarring associated with trauma, for example, surgical complications, chemotherapeutics drug- induced fibrosis (e.g. bleomycin-induced fibrosis), radiation-induced fibrosis, accidental injury and burns); retroperitoneal fibrosis (Ormond's disease); and peritoneal fibrosis/peritoneal scarring in patients receiving peritoneal dialysis, usually following renal transplantation. See, for example, Wynn et al, 2004, Nat Rev Immunol. August; 4(8): 583–594. The present invention therefore relates to methods of treatment or prevention, and compounds and compositions used in said methods, of fibrosis/fibrotic disorders of and/or associated with the major organs, including for example, the lung, liver, kidney, heart, skin, eye, gastrointestinal tract, peritoneum and bone marrow, and other diseases/disorders herein described.
The compounds may be combined with agents which are used as treatments for kidney disease, including anti-diabetic agents, cardiovascular disease agents, and novel agents targeting disease relevant pathways such as oxidative stress (including, but not limited to, the nrf2/keap-1 pathway) and anti-apoptotic pathways (including, but not limited to, anti p53 agents).
Interstitial lung disease (ILD) includes disorders in which pulmonary inflammation and fibrosis are the final common pathways of pathology, for example, sarcoidosis, silicosis, drug reactions, infections and collagen vascular diseases, such as rheumatoid arthritis and systemic sclerosis (scleroderma). The fibrotic disorder of the lung includes, for example, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), usual interstitial pneumonitis (UIP), interstitial lung disease, cryptogenic fibrosing alveolitis (CFA), bronchiolitis obliterans, and bronchiectasis.
Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD and has no known cause.
The compounds may be combined with agents which are treatments for IPF and potentially for ILD, including nintedanib and pirfenidone.
Liver cirrhosis has similar causes to ILD and includes, for example, cirrhosis associated with viral hepatitis, schistosomiasis and chronic alcoholism.
Kidney disease may be associated with diabetes, which can damage and scar the kidneys leading to a progressive loss of function, and also hypertensive diseases. Kidney fibrosis may occur at any stage of kidney disease, from chronic kidney disease (CKD), such as incident CKD and progressive CKD, through to end-stage renal disease (ESRD). Kidney fibrosis can develop as a result of cardiovascular disease such as hypertension or diabetes, both of which place immense strain on kidney function which promotes a fibrotic response. However, kidney fibrosis can also be idiopathic (without a known cause), and certain genetic mitochondrial diseases also present kidney fibrosis manifestations and associated symptoms.
Heart disease may result in scar tissue that can impair the ability of the heart to pump.
Diseases of the eye include, for example, macular degeneration and retinal and vitreal retinopathy, which can impair vision.
In a preferred embodiment, the present invention is directed to the treatment or prevention of idiopathic pulmonary fibrosis (IPF).
In another preferred embodiment, the present invention is directed to the treatment or prevention of kidney fibrosis.
In another preferred embodiment, the present invention is directed to the treatment or prevention of acute kidney injury (AKI), especially in high risk patients. Examples include post-surgical AKI, for example organ transplantation, such as due to ischemia reperfusion injury, delayed graft function; oncology, such as AKI due to chemotherapy; contrast medium-induced nephropathy, such as direct- tubular cytotoxicity, hemodynamic ischemia and osmotic effects; and acute interstitial nephritis, such as due to drugs or infection. A particular high risk patient sub-group are those undergoing cardiac surgery, for example, coronary artery bypass graft and/or valve surgery. There are established static risk factors for AKI such as age 65 years or over, insulin dependent diabetes, CKD (adults with an estimated glomerular filtration rate [eGFR] less than 60 ml/min/1.73 m2 are at particular risk), heart failure, liver disease, history of AKI. In another preferred embodiment, the present invention is directed to the treatment or prevention of chronic kidney disease (CKD) stemming from such AKI, including for example, tubulointerstitial fibrosis and diabetic nephropathy.
Leigh Syndrome is a rare inherited neurometabolic disorder that affects the central nervous system. This progressive disorder begins in infants between the ages of three months and two years. Rarely, it occurs in teenagers and adults. Leigh Syndrome can be caused by mutations in nuclear DNA encoding for mitochondrial proteins, mutations in mitochondrial DNA (maternally inherited leigh syndrome– MILS), or by deficiencies of an enzyme called pyruvate dehydrogenase located on the short arm of the X Chromosome (X-linked Leigh syndrome). Symptoms of Leigh syndrome usually progress rapidly. The earliest signs may be poor sucking ability, and the loss of head control and motor skills. These symptoms may be accompanied by loss of appetite, vomiting, irritability, continuous crying, and seizures. As the disorder progresses, symptoms may also include generalized weakness, lack of muscle tone, and episodes of lactic acidosis, which can lead to impairment of respiratory and kidney function.
In maternally inherited Leigh syndrome (MILS), genetic mutations in mitochondrial DNA (at a high proportion of >90%) interfere with the energy sources that run cells in an area of the brain that plays a role in motor movements. Genetic mutations in mitochondrial DNA result in a chronic lack of energy in these cells, which in turn affects the central nervous system and causes progressive degeneration of motor functions. When the genetic mutations in mitochondrial DNA that causes MILS are less abundant (less than 90%), the condition is known as neuropathy ataxia and retinitis pigmentosa (NARP). There is also a form of Leigh’s disease (called X-linked Leigh's disease) which is the result of mutations in a gene that produces another group of substances that are important for cell metabolism. A further variant of Leigh syndrome exists which is called French Canadian Variant, characterized by mutations in a gene called LRPPRC. Similar neurological symptoms are expressed as those for Leigh Syndrome, although Liver Steatosis is commonly also observed in the French Canadian Variant.
In a preferred embodiment, the present invention is directed to the treatment or prevention of Leigh syndrome or disease, including for example, X-linked Leigh's disease, Leigh Syndrome French Canadian Variant, and/or the symptoms associated with Leigh’s disease.
The compounds may be combined with novel agents which may be used as treatments for mitochondrial disease, including, but not limited to, nicotinamide riboside.
References to‘treatment’ includes means to ameliorate, alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis. The compounds of the invention are useful in the treatment of the diseases disclosed herein in humans and other mammals. In another embodiment, the invention encompasses prophylactic therapy of the diseases disclosed herein and includes means to prevent or slow the appearance of symptoms of the named disorder or condition. The compounds of the invention are useful in the prevention of the diseases disclosed herein in humans and other mammals.
A patient in need of treatment or prevention may, for example, be a human or other mammal suffering from the condition or at risk of suffering from the condition.
According to a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined herein, or a pharmaceutically acceptable salt of said compound or tautomer, together with a pharmaceutically acceptable diluent or carrier.
Pharmaceutical compositions of the invention comprise any of the compounds of the invention combined with any pharmaceutically acceptable carrier, adjuvant or vehicle. Examples of pharmaceutically acceptable carriers are known to those skilled in the art and include, but are not limited to, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms. The compositions may be in the form of, for example, tablets, capsules, powders, granules, elixirs, lozenges, suppositories, syrups and liquid preparations including suspensions and solutions. The term“pharmaceutical composition” in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers. The composition may further contain ingredients selected from, for example, diluents, adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms.
The compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents. The compounds may be combined with an additional anti-tumour therapeutic agent, for example, chemotherapeutic drugs or inhibitors of other regulatory proteins. In one embodiment, the additional anti-tumour therapeutic agent is a BH-3 mimetic. In a further embodiment, BH-3 mimetics may be selected from but not limited to one or more of ABT-737, ABT-199, ABT-263, and Obatoclax. In a further embodiment, the additional anti-tumour agent is a chemotherapeutic agent. Chemotherapeutic agents may be selected from but not limited to, olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin, ionizing radiation (IR), camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-fluoropyrimidines, gemcitabine, and doxorubicin. For the treatment or prevention of fibrotic disorders, for example, the compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of anticholinergic agents, beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, LTD4 antagonists, EGFR inhibitors and endothelin antagonists.
In particular, the compounds of the invention or pharmaceutical compositions thereof, as described herein, may be used alone or combined with one or more additional pharmaceutical agents selected from the group consisting of general immunosuppressive drugs, such as a corticosteroid, immunosuppressive or cytotoxic agents, or antifibrotics, such as pirfenidone or a non-specific kinase inhibitor (e.g. nintedanib).
The pharmaceutical compositions of the invention may be administered in any suitably effective manner, such as oral, parenteral, topical, inhaled, intranasal, rectal, intravaginal, ocular and aural. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in "Remington's Pharmaceutical Sciences", 19th Edition (Mack Publishing Company, 1995).
Oral Administration
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi-and nano- particulates, gels, films (including muco- adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001). A typical tablet may be prepared using standard processes known to a formulation chemist, for example, by direct compression, granulation (dry, wet, or melt), melt congealing, or extrusion. The tablet formulation may comprise one or more layers and may be coated or uncoated.
Examples of excipients suitable for oral administration include carriers, for example, cellulose, calcium carbonate, dibasic calcium phosphate, mannitol and sodium citrate, granulation binders, for example, polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethylcellulose and gelatin, disintegrants, for example, sodium starch glycolat and silicates, lubricating agents, for example, magnesium stearate and stearic acid, wetting agents, for example, sodium lauryl sulfate, preservatives, anti-oxidants, flavours and colourants.
Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled dual-, targeted and programmed release. Details of suitable modified release technologies such as high energy dispersions, osmotic and coated particles are to be found in Verma et al, Pharmaceutical Technology On-line, 25 (2), 1-14 (2001). Other modified release formulations are described in US Patent No.6,106,864.
Parenteral Administration
The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by suitable processing, for example, the use of high energy spray-dried dispersions and/or by the use of appropriate formulation techniques, such as the use of solubility-enhancing agents. Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed, sustained, pulsed, controlled dual, targeted and programmed release. Pharmaceutical compositions of the present invention also include compositions and methods known in the art for bypassing the blood brain barrier or can be injected directly into the brain. Suitable areas for injection include the cerebral cortex, cerebellum, midbrain, brainstem, hypothalamus, spinal cord and ventricular tissue, and areas of the PNS including the carotid body and the adrenal medulla.
Dosage
The magnitude of an effective dose of a compound will, of course, vary with the nature of the severity of the condition to be treated and the route of administration. The selection of appropriate dosages is within the remit of the physician. The daily dose range is about 10mg to about 100 mg per kg body weight of a human and non-human animal and in general may be around 10mg to 30mg per kg body weight per dose. The above dose may be given from one to three times per day.
For example, oral administration may require a total daily dose of from 5mg to 1000mg, such as from 5 to 500mg, while an intravenous dose may only require from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight. The total daily dose may be administered in single or divided doses.
The skilled person will also appreciate that, in the treatment or prevention of certain conditions, compounds of the invention may be taken as a single dose on an "as required" basis (i.e. as needed or desired). Synthetic methodologies
Compounds of formula (I) may be prepared using methods as described below in the general reaction schemes and the representative examples. Where appropriate, the individual transformations within a scheme may be completed in a different order. The invention is illustrated by the following non- limiting examples in which the following abbreviations and definitions are used. Compounds were characterised by liquid chromatography-mass spectroscopy (LCMS) or 1H NMR or both.
According to a further aspect, the present invention provides a process for the preparation of a compound of formula (I) comprising reacting a compound of formula (IV), where X is OH with an amine of formula (V), where PG is a protecting group, such as BOC or CBZ, to give an amide of formula (III) (Scheme 1). The amide-coupling reaction can be performed using standard methodology, for example by reaction using a coupling reagent such as DCC, HATU, HBTU, EDC or via a mixed anhydride. Alternatively, the acid (IV), where X is OH, can be converted into the acid chloride (IV), where X is Cl, using SOCl2, PCl3, or PCl5, which can then be reacted with the amine (V), preferably in a suitable solvent in the presence of a suitable base. Alternatively, the compound (IV), where X forms the ester, can be reacted directly with the amine (V), preferably in a suitable solvent. The compound of formula (III) may be deprotected using standard methods to give amine (II) which may then be reacted with cyanogen bromide to give the corresponding compound of formula (I).
Figure imgf000026_0001
In a further aspect, the present invention provides a compound, which is selected from formulae (II) and (III):
Figure imgf000026_0002
wherein PG is a protecting group, preferably BOC or CBZ, and R1, R2, R3, R4, R5 and R6 are as defined herein for the compound of formula (I) and preferred embodiments thereof, a tautomer thereof, or a salt of said compound or tautomer.
Abbreviations
br s Broad singlet (NMR signal)
d Doublet (NMR signal)
dba dibenzylacetone
DCM Dichloromethane
DME Dimethoxyethane
DMF N,N-Dimethylformamide
DMSO Dimethylsulfoxide
dppf 1,1'-Bis(diphenylphosphino)ferrocene
ES Electrospray EtOAc Ethyl acetate
h Hour(s)
m Multiplet (NMR signal)
Ms Mesyl/methanesulfonyl
MeOH Methanol
min Minute(s)
NMP N-Methylpyrrolidone
rt Room temperature
s Singlet (NMR signal)
TBD 1,5,7-Triazabicyclo[4.4.0]dec-5-ene TEA Triethylamine
TFA Trifluoroacetic acid
THF Tetrahydrofuran LCMS Methods
Method C
Figure imgf000027_0001
Method H
Figure imgf000028_0001
Method J
Figure imgf000028_0002
Method M
Figure imgf000029_0003
Example 1
N-((3R,5R)-1-Cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide
Figure imgf000029_0001
Building block synthesis
tert-Butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate
Figure imgf000029_0002
Scheme: (i) MsCl, TEA, DCM, 0 °C, 2 h; (ii) NaN3, DMF, 0 °C to 80 °C, 4 h; (iii) 3 M LiBH4 in THF, THF, -30 °C to rt, 3 h; then NaHCO3, -78 °C to rt, 16 h; (iv) MsCl, TEA, DCM, -10 °C to rt, 3 h; (v) LiI, THF, 0 °C to 60 °C, 3 h; (vi) H2, 10% Pd/C, TEA, MeOH, rt, 16 h. Step (i)
1-(tert-Butyl) 2-methyl (2S,4S)-4-((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate
This reaction was performed in duplicate. To a stirred solution of CAS 102195-79-9 (500 g, 2038.3 mmol, 1.0 eq, from Pharmablock) in DCM (5000 mL) was added triethylamine (411.7 g, 566 mL, 4076.6 mmol, 2.0 eq) followed by methanesulfonyl chloride (302.1 g, 305 mL, 2649.8 mmol, 1.3 eq) dropwise at 0 °C and the mixture was stirred for 2 h. This was poured into water (2500 mL) and the organic layer was separated and extracted with DCM (3000 mL). The organic phases were combined and washed with dilute citric acid solution (800 mL) and brine (1500 mL), dried over Na2SO4. After work up both the identical batches were combined and concentrated under reduced pressure to afford 1-(tert-butyl) 2-methyl (2S,4S)-4- ((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate as a brown semi-solid (1200 g, 3715.17 mmol, 91% yield).
LCMS: Method C, 1.51 min, MS: [M-56] 268.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 5.26 - 5.27 (m, 1H), 4.42 - 4.56 (m, 1H), 3.78 - 3.83 (m, 5H), 3.04 (s, 3H), 2.51 - 2.58 (m, 2H), 1.51 (s, 4.5H, Boc rotamer 1), 1.46 (s, 4.5H, Boc rotamer 2). This reaction was repeated on the same scale to yield further product (600 g, 1856 mmol, 91% yield).
Step (ii)
1-(tert-Butyl) 2-methyl (2S,4R)-4-azidopyrrolidine-1,2-dicarboxylate
To a stirred solution of 1-(tert-butyl) 2-methyl (2S,4S)-4-((methylsulfonyl)oxy)pyrrolidine-1,2- dicarboxylate (500 g, 1548.0 mmol, 1.0 eq) in DMF (5000 mL) was added NaN3 (139.3 g, 2322.0 mmol, 1.5 eq) portionwise at 0 °C. The reaction mixture was gradually heated to 80 °C for 4 h. The resulting reaction mixture was cooled to rt and poured into ice cold water (3500 mL) and extracted with EtOAc (3 x 3000 mL). The organic phases were combined and washed with ice cold water (4 x 1000 mL) and brine (2 x 1000 mL), dried over Na2SO4 and concentrated under reduced pressure to afford 1-(tert-butyl) 2-methyl (2S,4R)-4-azidopyrrolidine-1,2-dicarboxylate as a brown semi-solid (400 g, 1481.5 mmol, 95% yield).
LCMS: Method C, 1.65 min, MS: ES+ 271.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 4.36 - 4.39 (m, 1H), 4.20 - 4.27 (m, 1H), 3.65 - 3.68 (m, 3H), 3.51 - 3.58 (m, 1H), 3.38 - 3.41 (d, 1H), 2.29 - 2.38 (m, 1H), 2.10 - 2.19 (m, 1H), 1.40 (s, 4.5H, Boc rotamer 1), 1.34 (s, 4.5H, Boc rotamer 2). Further sub- title compound (400 g, 1470 mmol, 95% yield) was prepared by an identical method on a 252 g scale in duplicate.
Step (iii)
tert-Butyl (2S,4R)-4-azido-2-(hydroxymethyl)pyrrolidine-1-carboxylate
To a stirred solution of 1-(tert-butyl) 2-methyl (2S,4R)-4-azidopyrrolidine-1,2-dicarboxylate (300 g, 1111.1 mmol, 1.0 eq) in THF (3000 mL) was added 3 M LiBH4 solution in THF (47.2 g, 2166.7 mmol, 1.95 eq) dropwise at -30 °C. The reaction mixture was allowed to warm to rt and stirred for 3 h. The resulting reaction mixture was quenched by dropwise addition of a saturated aqueous solution of NaHCO3 (4000 mL) at -78 °C and stirred for 16 h at rt. The crude mixture was extracted with EtOAc (3 x 3000 mL) and washed with brine (1000 mL). The organic phase was dried over Na2SO4 and concentrated under reduced pressure to give a brown semi-solid (220 g). The crude semi-solid was purified by column chromatography (23% EtOAc in hexane) to obtain tert-butyl (2S,4R)-4-azido-2-(hydroxymethyl)pyrrolidine-1-carboxylate as a pale yellow liquid (202.5 g, 836.8 mmol, 75% yield).
LCMS: Method C, 1.51 min, MS: ES+ 243.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 4.77 (s, 1 H), 4.24 (s, 1H), 3.77 (br s, 1H), 3.33 - 3.46 (m, 4H), 2.10 - 2.15 (m, 1H), 1.98 - 1.99 (m, 1H), 1.39 (s, 9H). The reaction was further performed in duplicate on 2 x 250 g scale by an identical method to yield further sub-title compound (337.5 g, 1395 mmol, 75% yield).
Step (iv)
(2S,4R)-4-Azido-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-azido-2-(hydroxymethyl)pyrrolidine-1-carboxylate (440 g, 1818.2 mmol, 1.0 eq) in DCM (4400 mL) was added triethylamine (551.9 g (760 mL), 5454.5 mmol, 3.0 eq) at rt and stirred for 10 min, and then methanesulfonyl chloride (312.4 g, 2727.27 mmol, 1.5 eq) was added dropwise at -10 °C. The reaction mixture was slowly warmed to rt and stirred for 3 h. The resulting reaction mixture was poured into ice-cold water (4000 mL) and the organic phase was separated. The aqueous layer was extracted with DCM (2 x 2000 mL). The organic phases were combined and washed with dilute citric acid (2 x 1000 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford tert-butyl (2S,4R)-4-azido-2- (((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate as a brown liquid (550 g, quantitative yield). The crude material was directly used in the next step.
LCMS: Method M, 17.67 min, MS: [M-56] 265.0. The reaction was repeated on a 60 g scale by an identical method to yield further sub-title compounds (76 g, quantitative yield).
Step (v)
tert-Butyl (2S,4R)-4-azido-2-(iodomethyl)pyrrolidine-1-carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-azido-2-(((methylsulfonyl)oxy)methyl) pyrrolidine-1- carboxylate (550 g, 1718.8 mmol, 1.0 eq) in THF (5500 mL) was added lithium iodide (344.9 g, 2578.12 mmol, 1.5 eq) at 0 °C. The reaction mixture was slowly warmed to rt and then gradually heated at 60 °C for 3 h. The reaction mixture was cooled to rt, poured into ice-cold water (5000 mL) and extracted with EtOAc (3 x 2500 mL). The organic phases were combined and washed with brine (2000 mL), dried over Na2SO4 and concentrated under reduced pressure to give tert-butyl (2S,4R)-4- azido-2-(iodomethyl)pyrrolidine-1-carboxylate as a brown liquid (630 g). The crude material was purified by column chromatography (10% EtOAc in hexane) to afford tert-butyl (2S,4R)-4-azido-2- (iodomethyl)pyrrolidine-1-carboxylate as a light brown liquid (490 g, 1392 mmol, 76% yield over two steps). LCMS: Method M 21.64 min, MS: [M-56] 297.0; 1H NMR (400 MHz, DMSO-d6) d ppm: 4.32 (s, 1H), 3.34 - 3.71 (m, 5H), 2.19 (s, 1H), 1.91 - 1.95 (m, 1H), 1.42 (s, 9H). The reaction was repeated on a 76 g (237.5 mmol) scale by an identical method to yield further sub-title compound (60 g, 170.5 mmol, 68% yield over two steps).
Step (vi)
tert-Butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate
This reaction was performed in duplicate. To a stirred solution of tert-butyl (2S,4R)-4-azido-2- (iodomethyl)pyrrolidine-1-carboxylate (250 g, 709.9 mmol, 1.0 eq) in MeOH (2500 mL) was added triethylamine (79.0 g, 109 mL, 780.9 mmol, 1.1 eq) followed by palladium on carbon (125 g, 50% w/w) at rt under N2 atmosphere. The reaction mixture was purged with H2 gas for 16 h at rt. The identical batches were combined and filtered through a bed of Celite, washing with MeOH (5000 mL) and the filtrate was concentrated under reduced pressure to give a brown semi-solid. The crude material was poured into ice-cold water (2500 mL) and acidified with solid citric acid (pH 4). The acidic aqueous layer was washed with EtOAc (3 x 2500 mL) and then basified with solid NaHCO3 (pH 9) and extracted with EtOAc (3 x 3000 mL). The combined extracts were dried over Na2SO4 and concentrated under reduced pressure to yield tert-butyl (2R,4R)-4-amino-2-methylpyrrolidine-1- carboxylate as light brown liquid (240 g, 1200 mmol, 84% yield).
LCMS: Method J, 2.67 min, MS: [M-56] 144.8; 1H NMR (400 MHz, DMSO-d6) d ppm: 3.80 (s, 1H), 3.34 - 3.48 (m, 2H), 2.92 (s, 1H), 2.67 (br s, 2H), 1.74 - 1.70 (m, 1H), 1.62 (s, 1H), 1.38 (s, 9H), 1.09 (s, 3H).
Synthesis of Example 1
Figure imgf000032_0001
Scheme: (i) NaN(CHO)2, MeCN, 70 °C, 2 h; (ii) ethyl oxalyl chloride, K2CO3, DCM, 0 °C to rt, 3 h; (iii) POCl3, 100 °C, 16 h; (iv) TBD, THF, 0 °C to rt, 3 h; (v) TFA, DCM, 0 °C to rt, 3 h; (vi) K2CO3, CNBr, THF, 0 °C to rt, 2 h.
Step (i)
3-Glycylbenzonitrile HCl salt
To a stirred suspension of 3-(2-bromoacetyl)benzonitrile (CAS 50916-55-7, from Vyas Bio Life Science) (200 g, 892.9 mmol, 1 eq) in acetonitrile (2000 mL) was added sodium diformylamide (CAS 18197-26-7, from 1Click Chemistry, 101.8 g, 1071.4 mmol, 1.2 eq). The mixture was stirred at 70 °C for 2 h. The mixture was cooled to rt and concentrated under reduced pressure and the residue was diluted with methanol (1000 mL) and concentrated HCl (2000 mL) then heated at 70 °C for 1 h and allowed to cool to rt. The mixture was concentrated under reduced pressure to obtain crude compound which was further purified by crystallisation from isopropyl alcohol. The residue was suspended in isopropyl alcohol (500 mL) and allowed to stand for 16 h. The crystalline solid was collected by filtration and washed with n-pentane (200 mL) to afford 3-glycylbenzonitrile HCl salt (152 g, 779.5 mmol, 87% yield).
LCMS: Method C, 0.59 min, MS: ES+ 161.0; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.66 (br s, 3H), 8.53 (s, 1H), 8.30 - 8.32 (d, J = 8.0 Hz, 1H), 8.20 - 8.21 (d, J = 7.6 Hz, 1H), 7.79 - 7.83 (t, J = 8.0 Hz, 1H), 4.64 (s, 2H). The reaction was repeated on 50 g (Batch 1) and 92 g (Batch 2) by an identical method to yield 3-glycylbenzonitrile HCl salt (Batch 1: 37 g, 189.7 mmol, 85% yield; Batch 2: 70 g, 359 mmol, 87% yield).
Step (ii)
Ethyl 2-((2-(3-cyanophenyl)-2-oxoethyl)amino)-2-oxoacetate
To a stirred suspension of 3-glycylbenzonitrile HCl salt (150 g, 769.2 mmol, 1 eq) in DCM (1500 mL) was added potassium carbonate (318.5 g, 2307.7 mmol) at 0 °C. Ethyl oxalyl chloride (518.0 g, 1153.8 mmol, 1.5 eq) was added dropwise at 0 °C, the mixture stirred at rt for 3 h, then poured into cold water (1500 mL) and extracted with DCM (3 x 1000 mL). The combined organic phases were washed with brine (1500 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude material was triturated with pentane (500 mL) to afford ethyl 2-((2-(3- cyanophenyl)-2-oxoethyl)amino)-2-oxoacetate (130 g, 500 mmol, 65% yield).
LCMS: Method C, 1.45 min, MS: ES+ 261.3; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.22 (s, 1H), 8.49 (s, 1H), 8.26 - 8.28 (d, J = 8.0 Hz, 1H), 8.14 - 8.16 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 4.74 - 4.75 (d, J = 4.0 Hz, 2H), 4.24 - 4.30 (q, J = 8.0 Hz, 2H), 1.29 (t, J = 8.0 Hz, 3H). The reaction was repeated on a 100 g scale by an identical method to yield ethyl 2-((2-(3-cyanophenyl)-2- oxoethyl)amino)-2-oxoacetate (65 g, 250 mmol, 49% yield).
Step (iii)
Ethyl 5-(3-cyanophenyl) oxazole-2-carboxylate A stirred solution of ethyl 2-((2-(3-cyanophenyl)-2-oxoethyl)amino)-2-oxoacetate (130 g, 500 mmol) in POCl3 (390 mL, 3 volumes) was heated at 100 °C for 16 h. The mixture was cooled to rt and concentrated under reduced pressure, then poured into ice-cold water (2000 mL), basified with solid NaHCO3 to pH 8 and extracted with ethyl acetate (2 x 2000 mL). The combined organic phases were washed with brine (2000 mL), dried over Na2SO4 and evaporated under reduced pressure. The residue was triturated with methanol at -30 °C and dried under reduced pressure to afford ethyl 5-(3- cyanophenyl)oxazole-2-carboxylate (52 g, 214.9 mmol, 43% yield).
LCMS: Method C, 1.57 min, MS: ES+ 243.2; 1H NMR (400 MHz, DMSO-d6) d 8.34 (s, 1H), 8.11 - 8.16 (m, 2H), 7.93 - 7.94 (d, J = 4.0 Hz, 1H), 7.74 - 7.77 (m, 1H), 4.41 (q, J = 3.2 Hz, 2H), 1.36 (t, J = 3.6 Hz, 3H). The reaction was repeated on a 60 g scale by an identical method to yield ethyl 5-(3- cyanophenyl) oxazole-2-carboxylate (30 g, 124 mmol, 53% yield).
Step (iv)
tert-Butyl (2R,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-methyl pyrrolidine-1-carboxylate To a stirred solution of ethyl 5-(3-cyanophenyl) oxazole-2-carboxylate (80 g, 330.6 mmol, 1.0 eq) and tert-butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate (72.7 g, 363.6 mmol, 1.1 eq) in THF (800 mL) was added solution of triazabicyclodecene (59.7 g, 429.7 mmol, 1.3 eq) in THF (800 mL) dropwise at 0 °C. The mixture was slowly warmed to rt and stirred for 3 h, then poured into ice-cold water (1000 mL) and extracted with EtOAc (3 x 1500 mL). The combined organic phases were washed with brine (750 mL), dried over Na2SO4 and concentrated under reduced pressure to afford a dark brown solid (70 g). The crude material was purified by column chromatography (40% EtOAc in hexane) to afford tert-butyl (2R,4R)-4-(5-(3-cyanophenyl) oxazole-2-carboxamido)-2- methylpyrrolidine-1-carboxylate as light brown solid (58.4 g, 147.3 mmol, 44% yield).
LCMS: Method M, 18.76 min, MS: [M-56] 341.0; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.16 - 9.18 (d, J = 7.2 Hz, 1H), 8.36 (s, 1H), 8.15 - 8.17 (d, J = 6.4 Hz, 1H), 8.10 (s, 1H), 7.91 - 7.93 (d, J = 8.0 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 4.54 - 4.56 (m, 1H), 3.96 (m, 1H), 3.58 (m, 1H), 3.31 (m, 1H), 2.17 (m, 1H), 1.86 (m, 1H), 1.41 (s, 9H), 1.17 - 1.18 (d, J = 3.2 Hz, 3H).
Step (v)
5-(3-Cyanophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate To a stirred solution of tert-butyl (2R,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-methyl- pyrrolidine-1-carboxylate (57 g, 143.9 mmol, 1.0 eq) in DCM (570 mL) was added TFA (114 mL, 2 volumes) dropwise at 0 °C. The reaction mixture was slowly warmed to rt and stirred for 3 h. The mixture was concentrated under reduced pressure, and again with DCM (3 x 200 mL). The residue was triturated with diethyl ether (3 x 200 mL) and the solid was dried under reduced pressure to afford 5-(3-cyanophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate as a brown semi-solid (74 g, quantitative yield).
LCMS: Method J, 2.96 min, MS: ES+ 297.0. Step (vi)
N-((3R,5R)-1-Cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide
To a stirred solution of 5-(3-cyanophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate (74 g, 180.48 mmol, 1.0 eq) in THF (740 mL) was added K2CO3 (124.53 g, 902.43 mmol, 5.0 eq) followed by cyanogen bromide (19.11 g, 109.67 mmol, 1.0 eq) at 0 °C. The reaction mixture was slowly warmed to rt and stirred for 2 h. The resulting reaction mixture was poured into water (700 mL) and extracted with EtOAc (3 x 1000 mL). The organic layers were combined, washed with brine (500 mL), dried over Na2SO4 and concentrated under reduced pressure to afford a brown solid. The brown solid was triturated with diethyl ether, decanted and concentrated under reduced pressure. In order to remove traces of methanol, the material was washed with diethyl ether (2 x 500 mL) and then it was slurried in water (500 mL) prior to lyophilisation to afford N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl) oxazole-2- carboxamide as an off-white solid (39 g, 121.5 mmol, 84% yield over two steps).
LCMS: Method M, 15.03 min, MS: ES+ 322.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.36 - 9.38 (d, J = 8.0 Hz, 1H), 8.34 - 8.35 (s, 1H), 8.14-8.16 (d, J = 6.4 Hz, 1H), 8.09 (s, 1H), 7.90 - 7.93 (d, J = 6.4 Hz, 1H), 7.72 - 7.77 (t, J = 6.8 Hz, 1H), 4.49 (m, 1H), 3.88 - 3.92 (m, 1H), 3.73 - 3.79 (m, 1H), 3.41 - 3.43 (m, 1H), 2.12 - 2.16 (m, 1H), 1.73 - 1.79 (m, 1H), 1.23 - 1.26 (d, J =6.4 Hz, 3H).
Example 2
5-(3-Cyano-5-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
Figure imgf000035_0001
Step (i)
3-Acetyl-5-fluorobenzonitrile
To a stirred solution of 3-bromo-5-fluorobenzonitrile (CAS 179898-34-1, from Combiblocks, 2 g, 10 mmol) in toluene (28 mL) was added PPh3 (0.2 g, 0.8 mmol) and tributyl (1-ethoxyvinyl) tin (3.96 g, 10.9 mmol) under argon atmosphere. The reaction mixture was purged with argon for 10 min and Pd2(dba)3 (0.37 g, 0.4 mmol) was added. The mixture was heated at 100 °C for 16 h, then cooled to rt, acidified with 2N HCl (60 mL) and stirred at rt for 3 h before neutralizing with NaHCO3 solution (pH 7 to 8). The mixture was extracted with EtOAc (3 x 120 mL) and the organic phases were combined, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified by column chromatography (20% EtOAc in hexane) to obtain 3-acetyl-5- fluorobenzonitrile (1.1 g, 4.56 mmol, 67 % yield).
1H NMR (400 MHz, DMSO-d6) d ppm: 8.28 (t, J = 1.5 Hz, 1H), 8.17 (ddd, J = 8.4, 2.7, 1.3 Hz, 1H), 8.06 (ddd, J = 9.3, 2.6, 1.4 Hz, 1H), 2.64 (s, 3H). Step (ii)
3-(2-Bromoacetyl)-5-fluorobenzonitrile
To a stirred solution of 3-acetyl-5-fluorobenzonitrile (1.1 g, 6.74 mmol) in THF (10 mL), was added copper (II) bromide (3.0 g, 13.5 mmol) in portions. The mixture was stirred at rt for 48 h then poured into water (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic phases were washed with brine (100 mL), dried over Na2SO4 and concentrated under reduced pressure. The crude material was purified by column chromatography (5 % MeOH in DCM) to obtain 3-(2-bromoacetyl)- 5-fluorobenzonitrile (1.1 g, 4.56 mmol, 67% yield) which was used directly in the next step.
Step (iii)
3-Fluoro-5-glycylbenzonitrile hydrochloride
To a stirred solution of 3-(2-bromoacetyl)-5-fluorobenzonitrile (1.1 g, 4.58 mmol) in acetonitrile (10 mL) was added sodium diformylamide (0.52 g, 5.49 mmol). The reaction mixture was heated at 80 °C for 2 h then cooled to rt and methanol (10 mL) followed by concentrated HCl (2 mL) were added. The reaction mixture was heated to reflux for 1 h and then allowed to cool and concentrated under reduced pressure to give a dark brown semi-solid. The crude material was suspended in isopropyl alcohol (10 mL) to afford an off-white solid, which was filtered and then concentrated under reduced pressure to obtain 3-fluoro-5-glycylbenzonitrile.HCl salt (1.3 g, 6.04 mmol, quantitative yield).
LCMS: Method C, 0.93 min, MS: ES+ 178.0; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.43 - 8.41 (m, 2H), 8.38 - 8.28 (m, 1H), 8.28 - 8.17 (m, 1H), 8.09 - 8.07 (m, 1H), 4.66 (m, 2H).
Step (iv)
Ethyl 2-((2-(3-cyano-5-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate
To a solution of 3-fluoro-5-glycylbenzonitrile.HCl salt (1.3 g, 7.3 mmol) in DCM (15 mL) was added potassium carbonate (3.0 g, 21.9 mmol) followed by dropwise addition of ethyl oxalyl chloride (1.9 mL, 14.6 mmol) at 0 °C. The mixture was stirred at 0 °C for 2 h then poured into water (30 mL) and extracted with DCM (3 x 100 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (25 % EtOAc in hexane) to obtain ethyl 2-((2-(3-cyano-5-fluorophenyl)-2-oxoethyl) amino)-2-oxoacetate (0.19 g, 0.68 mmol, 11 % yield).
LCMS: Method C, 1.56 min, MS: ES+ 278.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.27 (s, 1H), 8.09 - 8.11 (m, 1H), 7.90 - 7.92 (m, 1H), 7.55 - 7.62 (br s, 1 H), 4.83 (s, 2 H), 4.31 - 4.42 (m, 2H), 1.32 - 1.43 (m, 3H).
Step (v)
Ethyl 5-(3-cyano-5-fluorophenyl)oxazole-2-carboxylate
A stirred solution of ethyl 2-((2-(3-cyano-5-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate (0.19 g, 0.68 mmol) in POCl3 (3 mL) was heated at 100 °C for 16 h. The reaction mixture was cooled to rt and poured into ice-cold water (20 mL). The mixture was basified with solid NaHCO3 and extracted with EtOAc (3 x 30 mL) and the combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude material was purified by column chromatography (10 % EtOAc in hexane) to obtain ethyl 5-(3-cyano-5-fluorophenyl)oxazole-2-carboxylate (0.08 g, 0.3 mmol, 45% yield).
LCMS: Method C, 1.67 min, MS: ES+ 260.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.22 (s, 2H), 8.02 (m, 2H), 4.41 (q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H).
Step (vi)
tert-Butyl (2R,4R)-4-(5-(3-cyano-5-fluorophenyl)oxazole-2-carboxamido)-2-methylpyrrolidine-1- carboxylate
To a stirred solution of ethyl 5-(3-cyano-5-fluorophenyl)oxazole-2-carboxylate (0.045 g, 0.17 mmol) and tert-butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate (CAS 348165-63-9, from Pharmablocks, 0.04 g, 0.2 mmol) in dry THF (1.5 mL) was added TBD (0.05 g, 0.34 mmol) under N2 at 0 °C. The mixture was slowly warmed to rt, stirred for 6 h then poured into water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The crude material was purified by column chromatography (30 % EtOAc in hexane) to yield tert-butyl (2R, 4R)-4-(5-(3-cyano-5-fluorophenyl)oxazole-2- carboxamido)-2-methylpyrrolidine-1-carboxylate (0.020 g, 0.048 mmol, 28% yield).
LCMS: Method C, 1.88 min, MS: ES+ 414.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.17 (d, J = 7.3 Hz, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 8.10 (d, J = 9.4 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 4.56 - 4.57 (m, 1H), 3.92 - 4.00 (m, 1H), 3.52 - 3.59 (m, 2H), 2.12 - 2.15 (m, 1H), 1.82 - 1.89 (m, 1H), 1.40 (s, 9H), 1.18 (br s, 3H).
Step (vii)
5-(3-Cyano-5-fluorophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
To a stirred solution of tert-butyl (2R, 4R)-4-(5-(3-cyano-5-fluorophenyl)oxazole-2-carboxamido)-2- methylpyrrolidine-1-carboxylate (0.02 g, 0.048 mmol) in DCM (2 mL) was added TFA (0.2 mL) dropwise at rt. The reaction mixture was stirred at rt for 2 h then concentrated under reduced pressure, azeotroped with DCM (2 x 10 mL) and concentrated under reduced pressure to afford 5-(3-cyano-5-fluorophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate (0.020 g, 96% yield).
LCMS: Method C, 1.33 min, MS: ES+ 312.1.
Step (viii)
To a stirred solution of 5-(3-cyano-5-fluorophenyl)-N-((3R, 5R)-5-methylpyrrolidin-3-yl) oxazole-2- carboxamide trifluoroacetate (0.02 g, 0.05 mmol) in dry THF (1.5 mL) was added K2CO3 (0.02 g, 0.14 mmol) followed by cyanogen bromide (0.007 g, 0.07 mmol) at 0 °C. The mixture was stirred for 1 h then poured into water (2 mL) and extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC (50 % EtOAc in hexane) to obtain 5-(3-cyano-5- fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide (0.003 g, 0.009 mmol, 18% yield).
LCMS: Method H, 3.39 min, MS: ES+339.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.38 (d, J = 6.8 Hz, 1H), 8.23 (s, 1H), 8.16 (s, 1H), 8.09 (d, J = 9.3 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 4.51 (s, 1H), 3.86 - 3.94 (m, 1H), 3.77 (dd, J = 9.6, 6.4 Hz, 1H), 3.43 (dd, J = 10.0, 3.7 Hz, 1H), 2.14– 2.19 (m, 1H), 1.77 -1.83 (m, 1H), 1.24 (d, J = 6.4 Hz, 3H).
Example 3
N-((3R,5R)-1-Cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)-4-methyloxazole-2-carboxamide
Figure imgf000038_0001
Step (i)
2-Bromo-1-(3-bromophenyl)propan-1-one
To a stirred solution of 1-(3-bromophenyl)propan-1-one (CAS 19829-31-3, from TCI, 1.5 g, 7.04 mmol) in 1,2-DME was added phenyltrimethylammonium tribromide (CAS 4207-56-1, from Avra, 5.28 g, 14.08 mmol) in portions at 0 °C. The mixture was stirred at 0 °C for 10 min and then at rt for 1.5 h before it was poured into water (40 mL) and extracted with EtOAc (2 x 40 mL). The organic phases were combined, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (100% hexane) to afford 2-bromo-1-(3- bromophenyl)propan-1-one (2.22 g, 7.65 mmol, >100% yield).
LCMS: Method C, 1.91 min; 1H NMR (400 MHz, CDCl3) d ppm: 8.19 (s, 1H), 7.98 - 7.99 (d, J = 7.6 Hz, 1H), 7.75 - 7.77 (d, J = 8.0 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 5.25 (q, J = 6.8 Hz, 1H), 1.94 - 1.95 (d, J = 6.4 Hz, 3H).
Step (ii)
2-Amino-1-(3-bromophenyl)propan-1-one hydrochloride
To a stirred suspension of 2-bromo-1-(3-bromophenyl)propan-1-one (2.12 g, 7.29 mmol) in acetonitrile (15 mL) was added sodium diformylamide (CAS 18197-26-7, from Ark Pharm, 0.83 g, 8.74 mmol). The mixture was stirred at 80 °C for 2 h, then cooled to rt and concentrated under reduced pressure; the residue was diluted with methanol (20 mL) and concentrated HCl (1.5 mL). The mixture was heated at 80 °C for 1 h then allowed to cool and concentrated under reduced pressure. The residue was suspended in isopropyl alcohol (10 mL), stirred for 15 min, filtered, and the solid was washed with isopropyl alcohol (5 mL) and dried under reduced pressure. Toluene (10 mL) was added and the mixture was concentrated under reduced pressure to yield 2-amino-1-(3- bromophenyl)propan-1-one HCl salt (2.8 g, 10.6 mmol, >100% yield). LCMS: Method C, 1.31 min, MS: ES+ 228.2, 230.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.56 (br s, 3H), 8.24 (s, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.96 (d, J =7.6 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 5.18 - 5.21 (m, 1H), 1.43 - 1.42 (d, J = 6.8 Hz, 3H).
Step (iii)
Ethyl 2-((1-(3-bromophenyl)-1-oxopropan-2-yl)amino)-2-oxoacetate
To a stirred suspension of 2-amino-1-(3-bromophenyl)propan-1-one hydrochloride (2.8 g, 10.63 mmol) in DCM (30 mL) was added K2CO3 (4.39 g, 31.9 mmol) in portions at 0 °C. Ethyl oxalyl chloride (3.62 g, 26.6 mmol) was added dropwise at 0 °C. The mixture was stirred at 0 °C for 1 h, then poured into water (100 mL) and extracted with DCM (3 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield ethyl 2-((1-(3- bromophenyl)-1-oxopropan-2-yl)amino)-2-oxoacetate (1.91 g, 5.84 mmol, 82% yield, over 3 steps). LCMS: Method C, 1.64min, MS: ES+ 328.5, 330.5.
Step (iv)
Ethyl 5-(3-bromophenyl)-4-methyloxazole-2-carboxylate
A stirred solution of ethyl 2-((1-(3-bromophenyl)-1-oxopropan-2-yl) amino)-2-oxoacetate (1.9 g, 5.79 mmol) in POCl3 (9.5 mL, 5 volumes) was heated at 110 °C for 2 h. The mixture was cooled to rt and slowly poured on to saturated NaHCO3 solution (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (21% EtOAc in hexane) to yield ethyl 5-(3-bromophenyl)-4-methyloxazole-2-carboxylate (1.25g, 4.07 mmol, 70% yield).
LCMS: Method C, 1.86 min, MS: ES+ 310.5, 312.5; 1H NMR (400 MHz, CDCl3) d ppm: 7.90 (s, 1H), 7.66 - 7.68 (d, J = 7.6 Hz, 1H), 7.55 - 7.57 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 8.0 Hz, 1H), 4.53 (q, J = 7.2 Hz, 2H), 2.55 (s, 3H), 1.49 (t, J = 7.2 Hz, 3H).
Step (v)
Lithium 5-(3-bromophenyl)-4-methyloxazole-2-carboxylate
To a stirred solution of ethyl 5-(3-bromophenyl)-4-methyloxazole-2-carboxylate (0.4 g, 1.29 mmol) in 1:1 THF/water (8 mL) was added LiOH.H2O (0.158 g, 3.87 mmol) at 0 °C. The mixture was stirred at rt for 1 h, then concentrated under reduced pressure to afford lithium 5-(3-bromophenyl)-4- methyloxazole-2-carboxylate (0.689 g, 2.40 mmol, >100% yield).
LCMS: Method C, 1.47 min, MS: ES+ 282.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 7.73 (s, 1H), 7.61 - 7.63 (d, J = 8.0 Hz, 1H), 7.54 - 7.56 (d, J = 8.4 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 2.39 (s, 3H). Step (vi)
tert-Butyl (2R,4R)-4-(5-(3-bromophenyl)-4-methyloxazole-2-carboxamido)-2-methylpyrrolidine-1- carboxylate
To a stirred solution of tert-butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate (0.41g, 2.13 mmol) and lithium 5-(3-bromophenyl)-4-methyloxazole-2-carboxylate (0.60 g, 2.13 mmol) in pyridine (10 mL) was added POCl3 (0.98 g, 0.6 mL, 6.38 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 10 min and then poured into ice-cold water (100 mL) and extracted with EtOAc (3 x 100 mL). The organic phases were combined, dried over Na2SO4 and concentrated under reduced pressure, and again with toluene (3 x 10 mL). The residue was purified by column chromatography (50% EtOAc in hexane) to yield tert-butyl (2R,4R)-4-(5-(3-bromophenyl)-4- methyloxazole-2-carboxamido)-2-methylpyrrolidine-1-carboxylate (0.28 g, 0.61 mmol, 29% yield). LCMS: Method C, 1.92 min, MS: ES+ 408.1, 410.1 (M-56); 1H NMR (400 MHz, CDCl3) d ppm: 7.89 (s, 1H), 7.65 -7.67 (d, J = 8.0 Hz, 1H), 7.54 - 7.56 (d, J = 8.0 Hz, 1H), 7.37 (t, J = 8.0 Hz, 1H), 7.04 - 7.06 (d, J = 7.6 Hz, 1H), 4.70 - 4.75 (m, 1H), 4.00 - 4.13 (m, 1H), 3.77 - 3.81 (m, 1H), 3.39 (m, 1H), 2.49 (s, 3H), 2.15 (m, 1H), 2.04 - 2.08 (m, 1H), 1.51 (s, 9H), 1.30 - 1.31 (d, J = 6.8 Hz, 3H). Step (vii)
tert-Butyl (2R,4R)-4-(5-(3-cyanophenyl)-4-methyloxazole-2-carboxamido)-2-methylpyrrolidine-1- carboxylate
To a stirred solution of tert-butyl (2R,4R)-4-(5-(3-bromophenyl)-4-methyloxazole-2-carboxamido)-2- methylpyrrolidine-1-carboxylate (0.26 g, 0.56 mmol) in NMP (8 mL) was added zinc cyanide (0.098 g, 0.84 mmol), and dppf (0.31 g, 0.56 mmol). The mixture was degassed and purged with N2 for 15 min and then Pd2(dba)3 (0.256 g, 0.28 mmol) was added. The mixture was heated at 160 °C for 1 h in the microwave then poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The organic phases were combined, dried over Na2SO4 and concentrated under reduced pressure. This was purified by column chromatography (51% EtOAc in hexane) to afford tert-butyl (2R, 4R)-4-(5- (3-cyanophenyl)-4-methyloxazole-2-carboxamido)-2-methylpyrrolidine-1-carboxylate (0.24 g, 0.60 mmol, >100% yield).
LCMS: Method C, 1.75 min, MS: ES+ 411.6; 1H NMR (400 MHz, CDCl3) d ppm: 7.98 - 8.00 (m, 2H), 7.69 - 7.71 (d, J = 7.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.06 - 7.08 (d, J = 7.6 Hz, 1H), 4.72 (q, J = 6.4 Hz, 1H), 4.06 - 4.11 (m, 1H), 3.77 - 3.82 (m, 1H), 3.38 - 3.44 (m, 1H), 2.52 (s, 3H), 2.17 (m, 1H), 2.05 - 2.09 (m, 1H), 1.52 (s, 9H), 1.32 (br, s, 3H).
Step (viii)
5-(3-Cyanophenyl)-4-methyl-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
To a stirred solution of tert-butyl (2R,4R)-4-(5-(3-cyanophenyl)-4-methyloxazole-2-carboxamido)-2- methylpyrrolidine-1-carboxylate (0.24 g, 0.60 mmol) in DCM (5 mL) was added TFA (1.22 mL, 5 volumes) dropwise at 0 °C. The mixture was slowly warmed to rt and stirred for 1 h then concentrated under reduced pressure, and again with DCM (3 x 10 mL). The residue was triturated with diethyl ether (20 mL) and the solid was dried under reduced pressure to afford 5-(3-cyanophenyl)-4-methyl-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate (0.278 g, 0.66 mmol, >100 % yield).
LCMS: Method C, 1.35 min, MS: ES+ 311.3. Step (ix)
N-((3R, 5R)-1-Cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)-4-methyloxazole-2-carboxamide To a stirred solution of 5-(3-cyanophenyl)-4-methyl-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate (0.28 g, 0.66 mmol) in THF (10 mL) was added K2CO3 (0.36 g, 2.62 mmol) followed by cyanogen bromide (0.05 g, 0.52 mmol) at 0 °C. The mixture was slowly warmed to rt and stirred for 20 min then poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected to column chromatography (62% EtOAc in hexane) to afford N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)-4-methyloxazole-2-carboxamide (0.10 g, 0.31 mmol, 67% yield over 3 steps).
LCMS: Method H, 5.15 min, MS: ES- 334.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.34 - 9.36 (d, J = 6.4 Hz, 1H), 8.14 (s, 1H), 8.03 - 8.05 (d, J = 7.6 Hz, 1H), 7.91 - 7.92 (d, J = 7.6 Hz, 1H), 7.76 (t, J = 8.0 Hz, 1H), 4.49 - 4.50 (m, 1H), 3.89 - 3.90 (m, 1H), 3.73 - 3.77 (m, 1H), 3.41 - 3.43 (m, 1H), 2.47 (s, 3H), 2.41 (m, 1H), 1.73 - 1.80 (m, 1H), 1.23 - 1.24 (d, J = 6.0 Hz, 3H).
Example 4
N-((3R,5S)-1-Cyano-5-(fluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide
Figure imgf000041_0001
Step (i)
Lithium 5-(3-cyanophenyl)oxazole-2-carboxylate
To a stirred solution of ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (Example 1, step 3, 0.2 g, 0.83 mmol, 1 eq) in 4:1 THF/water (5 mL) was added LiOH.H2O (0.03 g, 0.83 mmol, 1 eq) at 0 °C. The mixture was stirred at rt for 3 h then concentrated under reduced pressure and the residue was triturated with acetone (2 x 10 mL) to afford lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.22 g, 0.98 mmol, >100% yield).
LCMS: Method C, 1.32 min, MS: ES+ 215.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 8.20 (s, 1H), 8.01 - 8.03 (d, J = 8.0 Hz, 1H), 7.81 - 7.83 (d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.7 (t, J = 8.0 Hz, 1H). Step (ii)
tert-Butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-(fluoromethyl)pyrrolidine-1- carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-amino-2-(fluoromethyl)pyrrolidine-1-carboxylate (CAS 120783-03-9, from Angene) (0.102g, 0.47 mmol, 1.0 eq) and lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.10 g, 0.47 mmol, 1.0 eq) in pyridine (2 mL) was added POCl3 (0.214 g, 0.12 mL, 1.40 mmol 3.0 eq) dropwise at 0 °C. The mixture was stirred at 0 °C for 20 min and then poured into ice-cold water (25 mL) and extracted with EtOAc (3 x 25 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude material was washed with toluene (4 x 10 mL) to yield tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2- carboxamido)-2-(fluoromethyl)pyrrolidine-1-carboxylate (0.19 g, 0.47 mmol, >100% yield).
LCMS: Method C, 1.65 min, MS: ES+ 359.2 (M-56); 1H NMR (400 MHz, DMSO-d6) d ppm: 9.21 - 9.23 (d, J = 7.2 Hz, 1H), 8.37 (s, 1H), 8.16 - 8.18 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.95 - 7.93 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 7.16 - 7.29 (m, 2H), 4.54 - 4.59 (m, 2H), 4.07 - 4.15 (m, 1H), 3.52 - 3.59 (m, 1H), 2.32 - 2.35 (m, 1H), 2.20 (m, 1H), 1.43 (s, 9H).
Step (iii)
5-(3-Cyanophenyl)-N-((3R,5S)-5-(fluoromethyl)pyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
To a stirred solution of tert-butyl (2R,4R)-4-(6-(3-cyanophenyl)pyrimidine-4-carboxamido)-2- methylpyrrolidine-1-carboxylate (0.19 g, 0.46 mmol, 1.0 eq) in DCM (5 mL) was added TFA (0.95 mL, 5 volumes) dropwise at 0 °C. The mixture was stirred at rt for 3 h and then concentrated with DCM (3 x 10 mL) under reduced pressure to obtain 5-(3-cyanophenyl)-N-((3R,5S)-5- (fluoromethyl)pyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate (0.24 g, 0.57 mmol, >100% yield).
LCMS: Method C, 1.33 min, MS: ES+ 315.3; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.45 (br s, 1H), 9.37 - 9.39 (d, J = 6.8 Hz, 1H), 9.22 (br s, 1H), 8.36 (s, 1H), 8.17 (s, 1H), 8.15 (s, 1H), 7.94 - 7.96 (d, J = 7.6 Hz, 1H), 7.77 (t, J = 7.6 Hz, 1H), 4.57 - 4.85 (m, 3H), 4.18 (m, 1H), 3.58 (m, 1H), 3.38 - 3.36 (m, 1H), 2.35 - 2.21 (m, 1H), 2.15 - 2.07 (m, 1H).
Step (iv)
To a stirred solution of 5-(3-cyanophenyl)-N-((3R,5S)-5-(fluoromethyl)pyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate (0.24 g, 0.56 mmol, 1.0 eq) in THF (5 mL) was added potassium carbonate (0.23 g, 1.68 mmol, 3 eq) in portions at 0 °C. Cyanogen bromide (0.048 g, 0.45 mmol, 0.8 eq) was added and the mixture was stirred at 0 °C for 20 min. The mixture was poured into ice- cold water (30 mL) and was extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (60 - 120# silica gel, 72% EtOAc in hexane) to yield N-((3R,5S)-1-cyano-5- (fluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.07 g, 0.20 mmol, 44% yield over 2 steps).
LCMS: Method H, 3.21 min, MS: ES-338.0; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.42 - 9.44 (d, J = 6.8 Hz, 1H), 8.37 (s, 1H), 8.16 - 8.18 (d, J = 8.0 Hz, 1H), 8.13 (s, 1H), 7.93 - 7.95 (d, J = 7.6 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 4.43 - 4.69 (m, 3H), 4.17 - 4.23 (m, 1H), 3.74 - 3.78 (m, 1H), 3.47 - 3.51 (dd, J = 9.6, 4.0 Hz, 1H), 2.15 - 2.21 (m, 1H), 1.99 - 2.04 (m, 1H). Example 5
N-((3R,5S)-1-Cyano-5-(difluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide
Figure imgf000043_0001
Step (i)
tert-Butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-(difluoromethyl)-pyrrolidine-1- carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-amino-2-(difluoromethyl)pyrrolidine-1-carboxylate (CAS 1207852-96-7, from Synthonix) (0.09 g, 0.37 mmol) and lithium 5-(3-cyanophenyl)oxazole-2- carboxylate (Example 4, step 1) (0.08g, 0.37 mmol) in pyridine (2 mL) was added POCl3 (0.17 g, 0.1 mL, 1.12 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 20 min and then poured into ice cold water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to obtain tert-butyl (2S, 4R)-4-(5-(3- cyanophenyl)oxazole-2-carboxamido)-2-(difluoromethyl)-pyrrolidine-1-carboxylate (0.17 g, 0.40 mmol, >100% yield).
LCMS: Method C, 1.76 min, MS: ES+377.3 (M-56); 1H NMR (400 MHz, DMSO-d6) d ppm: d 9.27 - 9.29 (d, J = 7.2 Hz, 1H), 8.37 (s, 1H), 8.15 - 8.17 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.92 - 7.94 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 6.06 - 6.35 (m, 1H), 4.57 - 4.58 (m, 1H), 4.27 - 4.31 (m, 1H), 3.40 - 3.56 (m, 2H), 2.15 - 2.35 (m, 2H), 1.43 (s, 9H).
Step (ii)
5-(3-Cyanophenyl)-N-((3R,5S)-5-(difluoromethyl)pyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
To a stirred solution of tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2- (difluoromethyl)pyrrolidine-1-carboxylate (0.165 g, 0.38 mmol, 1.0 eq) in DCM (5 mL) was added TFA (0.8 mL, 5 volumes) dropwise at 0 °C. The mixture was stirred at rt for 3 h then concentrated with DCM (3 x 10 mL) under reduced pressure to obtain 5-(3-cyanophenyl)-N-((3R,5S)-5- (difluoromethyl)pyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate (0.22 g, 0.49 mmol, >100% yield).
LCMS: Method C, 1.33 min, MS: ES+ 315.3; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.84 (br s, 1H), 9.40 - 9.41 (d, J = 6.8 Hz, 1H), 8.36 (s, 1H), 8.17 (s, 1H), 8.15 (s, 1H), 7.91 - 7.94 (d, J = 10.8 Hz, 1H), 7.77 (t, J = 7.6 Hz, 1H), 6.32 - 6.81 (m, 1H), 4.64 - 4.66 (m, 1H), 4.35 (m, 1H), 3.57 - 3.62 (m, 1H), 3.39 - 3.44 (m, 1H), 2.33 - 2.35 (m, 2H). Step (iii)
N-((3R,5S)-1-Cyano-5-(difluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of 5-(3-cyanophenyl)-N-((3R,5S)-5-(fluoromethyl)pyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate (0.21 g, 0.47 mmol, 1.0 eq) in THF (5 mL) was added potassium carbonate (0.195 g, 1.41 mmol, 3 eq) in portions at 0 °C. Cyanogen bromide (0.04 g, 0.38 mmol, 0.8 eq) was added and the mixture was stirred at 0 °C for 20 min, then poured into ice cold water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (60 - 120# silica gel, 66% EtOAc in hexanes) to yield N-((3R,5S)-1-cyano-5- (difluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.045 g, 0.13 mmol, 33 % yield over 3 steps).
LCMS: Method H, 3.41 min, MS: ES+ 358.1; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.43 -9.45 (d, J = 6.8 Hz, 1H), 8.36 (s, 1H), 8.15 - 8.17 (d, J = 8.0 Hz, 1H), 8.13 (s, 1H), 7.93 - 7.95 (d, J = 7.6 Hz, 1H), 7.77 (t, J = 8.0 Hz, 1H), 6.07 - 6.35 (m, 1H), 4.54 - 4.59 (m, 1H), 4.29 - 4.35 (m, 1H), 3.75 - 3.79 (m, 1H), 3.47 - 3.51 (dd, J = 9.6, 5.2 Hz, 1H), 2.24 - 2.35 (m, 1H), 2.13 - 2.19 (m, 1H).
Example 6
N-((3R,5S)-1-Cyano-5-(methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide
Figure imgf000044_0001
Step (i)
tert-Butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-(methoxymethyl)pyrrolidine-1- carboxylate
To a stirred solution of tert-butyl-(2S,4R)-4-amino-2-(methoxymethyl)pyrrolidine-1-carboxylate (CAS 1207853-53-9, 0.14 g, 0.62 mmol, 1.0 eq) and ethyl 5-(3-cyanophenyl)oxazole-2-carboxylate (0.22 g, 0.93 mmol, 1.5 eq) in THF (5 mL) was added TBD (0.13 g, 0.93 mmol, 1.5 eq) at 0 °C. The mixture was stirred at rt for 3 h and then poured into water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2- (methoxymethyl)-pyrrolidine-1-carboxylate (0.26 g). LCMS: Method C, 1.66 min, MS: ES+ 327.2 (M-56); 1H NMR (400 MHz, CDCl3) d ppm: 8.08 (s, 1H), 8.02 - 8.04 (d, J = 8.0 Hz, 1H), 7.71 - 7.73 (d, J = 7.6 Hz, 1H), 7.64 (t, J = 7.6 Hz, 1H), 7.53 (s, 1H), 7.09 - 7.11 (d, J = 8.0 Hz, 1H), 4.76 - 4.81 (m, 1H), 4.08 - 4.15 (m, 1H), 3.8 (m, 1H), 3.45 - 3.65 (m, 3H), 3.41 (s, 3H), 2.42 (m, 1H), 2.09 (m, 1H), 1.51 (s, 9H). Step (ii)
5-(3-Cyanophenyl)-N-((3R,5S)-5-(methoxymethyl)pyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
To a stirred solution of tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2- (methoxymethyl)pyrrolidine-1-carboxylate (0.22 g, 0.52 mmol, 1.0 eq) in DCM (5 mL) was added TFA (2.2 mL, 10 volumes) dropwise at 0 °C. The mixture was stirred at rt for 1 h and concentrated under reduced pressure. The residue was triturated with diethyl ether (5 mL) to obtain 5-(3- cyanophenyl)-N-((3R,5S)-5-(methoxymethyl)pyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate (0.25 g, 0.57 mmol). LCMS: Method C, 1.30 min, MS: ES+ 327.2.
Step (iii)
N-((3R,5S)-1-Cyano-5-(methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide To a stirred solution of 5-(3-cyanophenyl)-N-((3R,5S)-5-(methoxymethyl)pyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate (0.25 g, 0.57 mmol, 1.0 eq) in THF (5 mL) was added K2CO3 (0.23 g, 1.70 mmol, 3 eq) in portions at rt. The mixture was cooled to 0 °C, a solution of cyanogen bromide (0.048 g, 0.45 mmol, 0.8 eq) in THF (2 mL) was added and the mixture was stirred at rt for 1 h. The mixture was poured into water (50 mL) and extracted with EtOAc (3 x 15 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (60 - 120# silica gel, 55% EtOAc in hexanes) to yield N-((3R,5S)-1-cyano-5- (methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.08 g, 0.23 mmol, 25% yield over 3 steps). LCMS: Method H, 3.03 min, MS: ES+ 352.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.35 - 9.37 (d, J = 6.8 Hz, 1H), 8.37 (s, 1H), 8.15 - 8.17 (d, J = 7.6 Hz, 1H), 8.12 (s, 1H), 7.93 - 7.94 (d, J = 7.6 Hz, 1H), 7.77 (t, J = 7.6 Hz, 1H), 4.51 - 4.52 (m, 1H), 4.04 (m, 1H), 3.71 (t, J = 8.8 Hz, 1H), 3.42 - 3.50 (m, 3H), 3.34 (s, 3H), 2.12 - 2.15 (m, 1H), 1.97 - 2.02 (m, 1H).
Example 7
N-((3R,5S)-1-Cyano-5-((dimethylamino)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide
Figure imgf000045_0001
Step (i)
tert-Butyl (2S, 4R)-4-azido-2-((dimethylamino)methyl)pyrrolidine-1-carboxylate
To a stirred solution of dimethylamine HCl (0.699 g, 8.52 mmol) in DMF (12 mL) was added K2CO3 (3.9 g, 28.4 mmol) followed by a solution of tert-butyl (2S,4R)-4-azido-2-(iodomethyl)pyrrolidine-1- carboxylate (2.0 g, 5.68 mmol) in DMF (3 mL). The mixture was heated at 120 °C for 16 h then poured into ice-cold water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was subjected to column chromatography (40-100% EtOAc in hexanes) to obtain tert-butyl (2S, 4R)-4-azido-2- ((dimethylamino)methyl)pyrrolidine-1-carboxylate (0.90 g, 3.35 mmol, 59% yield).
LCMS: Method C, 1.34 min, MS: ES+ 270.4.
Step (ii)
tert-Butyl (2S, 4R)-4-amino-2-((dimethylamino)methyl)pyrrolidine-1-carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-azido-2-((dimethylamino)methyl)pyrrolidine-1- carboxylate (0.8 g, 2.97 mmol) in THF (20 mL) was added 10% Pd/C (50% moist, 0.4 g). The reaction mixture was purged with H2 gas for 1 h then filtered through a bed of celite, washed with THF (20 mL) and filtrate was concentrated under reduced pressure to afford tert-butyl (2S,4R)-4- amino-2-((dimethylamino)methyl)pyrrolidine-1-carboxylate (0.62 g, 2.55 mmol, 86% yield).
LCMS: Method H, 2.36 min, MS: ES+ 244.2.
Step (iii)
tert-Butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2-((dimethylamino)methyl)- pyrrolidine-1-carboxylate
To a stirred solution of tert-butyl (2S,4R)-4-amino-2-((dimethylamino)methyl)pyrrolidine-1- carboxylate (0.30 g, 1.22 mmol) and lithium 5-(3-cyanophenyl)oxazole-2-carboxylate (0.54 g, 2.44 mmol) in THF (7 mL) was added TEA (0.28 g, 2.80 mmol) and 1-propanephosphonic anhydride (2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide, 50% solution in EtOAc, 1.55 mL, 2.44 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 3 h then poured into water (40 mL) and extracted with EtOAc (2 x 40 mL). The combined organic phases were combined, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by column chromatography (8.5% MeOH in DCM) to afford tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2- carboxamido)-2-((dimethylamino)methyl)pyrrolidine-1-carboxylate (0.08 g, 0.18 mmol, 15% yield). LCMS: Method C, 1.44 min, MS: ES+ 440.5.
Step (iv)
5-(3-Cyanophenyl)-N-((3R,5S)-5-((dimethylamino)methyl)pyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate
To a stirred solution of tert-butyl (2S,4R)-4-(5-(3-cyanophenyl)oxazole-2-carboxamido)-2- ((dimethylamino)methyl)pyrrolidine-1-carboxylate (0.08 g, 0.18 mmol) in DCM (3 mL) was added TFA (0.8 mL, 10 volumes) dropwise at 0 °C. The mixture was slowly warmed to rt and stirred for 5 h, then concentrated under reduced pressure and again with DCM (3 x 10 mL) to afford 5-(3-cyanophenyl)-N-((3R,5S)-5-((dimethylamino)methyl)pyrrolidin-3-yl)oxazole-2-carboxamide trifluoroacetate (0.13 g, 0.29 mmol, >100 % yield).
LCMS: Method C, 1.23 min, MS: ES+ 340.4. Step (v)
N-((3R,5S)-1-Cyano-5-((dimethylamino)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide
To a stirred solution of 5-(3-cyanophenyl)-N-((3R,5S)-5-((dimethylamino)methyl)pyrrolidin-3- yl)oxazole-2-carboxamide trifluoroacetate (0.13 g, 0.29 mmol) in THF (10 mL) was added potassium carbonate (0.20 g, 1.43 mmol, 5.0 eq) followed by cyanogen bromide (0.024 g, 0.23 mmol) at 0 °C. The mixture was slowly warmed to rt and stirred for 1 h then poured into water (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative HPLC (phases: (a) 5 mM ammonium bicarbonate / 0.1 % NH3 in water; (b) 100% MeCN) to obtain N-((3R, 5S)-1-cyano-5- ((dimethylamino)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide (0.017 g, 0.047 mmol, 26% yield over 2 steps).
LCMS: Method M, 11.13 min, MS: ES+ 365.2; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.37 (br s, 1H), 8.35 (s, 1H), 8.13 - 8.15 (d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.91 -7.93 (d, J = 7.6 Hz, 1H), 7.75 (t, J = 7.6 Hz, 1H), 4.47 (br s, 1H), 3.97 - 4.01 (m, 1H), 3.69 - 3.73 (m 1H), 3.38 - 3.41 (dd, J = 10.0, 4.0 Hz, 1H), 2.41 - 2.45 (m, 1H), 2.33 - 2.88 (m, 1H), 2.19 (s, 6H), 2.11 - 2.16 (m, 1H), 1.86 - 1.93 (m, 1H).
Example 8
5-(3-Cyano-4-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
Figure imgf000047_0001
Step (i)
5-(2-Bromoacetyl)-2-fluorobenzonitrile
Prepared analogously to 3-(2-bromoacetyl)-5-fluorobenzonitrile (towards Example 2) from 5-acetyl- 2-fluorobenzonitrile (CAS 288309-07-9). LCMS: Method C, 1.56 min, MS: ES- 239.9.
Step (ii)
2-Fluoro-5-glycylbenzonitrile
Prepared analogously to 3-fluoro-5-glycylbenzonitrile. LCMS: Method C, 0.96 min, MS: ES+ 179.1. Step (iii)
Ethyl 2-((2-(3-cyano-4-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate
Prepared analogously to ethyl 2-((2-(3-cyano-5-fluorophenyl)-2-oxoethyl)amino)-2-oxoacetate.
LCMS: Method C, 1.46 min, MS: ES+ 279.2. Step (iv)
Ethyl 5-(3-cyano-4-fluorophenyl)oxazole-2-carboxylate
Prepared analogously to ethyl 5-(3-cyano-5-fluorophenyl)oxazole-2-carboxylate.
LCMS: Method C, 1.66 min, MS: ES+ 261.2.
Step (v)
tert-Butyl (2R,4R)-4-(5-(3-cyano-4-fluorophenyl)oxazole-2-carboxamido)-2-methylpyrrolidine-1- carboxylate
To a stirred solution of ethyl 5-(3-cyano-4-fluorophenyl)oxazole-2-carboxylate (0.30 g, 1.15 mmol) in toluene (5 mL) was added tert-butyl (2R,4R)-4-amino-2-methylpyrrolidine-1-carboxylate (0.23 g, 1.15 mmol) followed by triethylamine (0.35 g, 3.46 mmol). The mixture was stirred for 5 min at 0 °C, then trimethylaluminum (2M in hexane, 0.17 g, 1.2 mL, 2.31 mmol) was added and the mixture was heated at 90 °C for 18 h. The mixture was poured into water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude material was purified by flash column chromatography (silica gel, 4% in methanol in DCM) to yield tert-butyl (2R,4R)-4-(5-(3-cyano-4-fluorophenyl)oxazole-2-carboxamido)- 2-methyl pyrrolidine-1-carboxylate (0.11 g, 0.26 mmol, 23% yield).
LCMS: Method C, 1.75 min, MS: ES- 413.6.
Step (vi)
5-(3-Cyano-4-fluorophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide
trifluoroacetate
Prepared from tert-butyl (2R,4R)-4-(5-(3-cyano-4-fluorophenyl)oxazole-2-carboxamido)-2-methyl pyrrolidine-1-carboxylate analogously to 5-(3-cyano-5-fluorophenyl)-N-((3R,5R)-5-methylpyrrolidin- 3-yl)oxazole-2-carboxamide. LCMS: Method C, 1.31 min, MS: ES+ 315.3.
Step (vii)
5-(3-Cyano-4-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide Prepared from 5-(3-cyano-4-fluorophenyl)-N-((3R,5R)-5-methylpyrrolidin-3-yl)oxazole-2- carboxamide trifluoroacetate analogously to Example 2.
LCMS: Method H, 3.26 min, MS: ES- 338; 1H NMR (400 MHz, DMSO-d6) d ppm: 9.37 (d, J = 6.8 Hz, 1H), 8.46 (d, J = 4.0 Hz, 1H), 8.21 - 8.24 (m, 1H), 8.05 (s, 1H), 7.74 (dd, J = 9.2 Hz, 8.8 Hz, 1H), 4.50 - 4.51 (m, 1H), 3.88 - 3.93 (m, 1H), 3.75 - 3.79 (m, 1H), 3.41 - 3.44 (m, 1H), 2.13 - 2.16 (m, 1H), 1.74 - 1.81 (m, 1H), 1.25 (d, J = 6.4 Hz, 3H). Biological Activity of Compounds of the Invention
Abbreviations:
TAMRA carboxytetramethylrhodamine
PCR polymerase chain reaction
PBS phosphate buffered saline EDTA ethylenediaminetetraacetic acid
Tris 2-amino-2-(hydroxymethyl)-1,3-propanediol
NP-40 Nonidet P-40, octylphenoxypolyethoxyethanol
BSA bovine serum albumin
PNS peripheral nervous system
BH3 Bcl-2 homology domain 3
PTEN phosphatase and tensin homologue
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
DMSO Dimethyl sulfoxide
YFP Yellow fluorescent protein
VME Vinyl methyl ester
HA Hemagglutinin
Ahx Aminohexanoic acid
USP30 biochemical IC50 assay
Dilution plates were prepared at 21 times the final concentration (2100µM for a final concentration of 100µM) in 50% DMSO in a 96-well polypropylene V-bottom plate (Greiner #651201). A typical 8-point dilution series would be 100, 30, 10, 3, 1, 0.3, 0.1, 0.03µM final. Reactions were performed in duplicate in black 384 well plates (small volume, Greiner 784076) in a final reaction volume of 21 µl. Either 1µl of 50% DMSO or diluted compound was added to the plate. USP30 (Boston Biochem #E582) was diluted in reaction buffer (40mM Tris, pH 7.5, 0.005% Tween 20, 0.5mg/ml BSA, 5 mM beta-mercaptoethanol) to achieve a final assay concentration of 4 nM, and 10µl of diluted USP30 was added to the compound. Enzyme and compound were incubated for 30 min at room temp. Reactions were initiated by the addition of 50nM of TAMRA labelled peptide linked to ubiquitin via an iso-peptide bond as fluorescence polarisation substrate. Reactions were read immediately after addition of substrate and following a 2-hour incubation at room temperature. Readings were performed on a Pherastar Plus (BMG Labtech). l Excitation 540 nm; l Emission 590 nm.
Activity of exemplary compounds in USP30 biochemical IC50 assay:
Figure imgf000049_0001
Reference Examples
Activity of exemplary compounds in USP30 biochemical IC50 assay:
Figure imgf000050_0001
Deubiquitylating Enzyme (DUB) Selectivity
Activity of exemplary compounds in DUB biochemical IC50 assays:
Figure imgf000050_0002
Figure imgf000050_0003
Off-Target Pharmacology
Examples 1 and 6 were subject to pharmacological profiling in the Eurofins CEREP SafetyScreen44 panel. At a single concentration of 10 mM, less than 50% inhibition of binding or enzyme activity was observed against all targets in the panel for both compounds, apart from MAO-A for Example 1, which showed inhibition of 72%. Follow up multiple concentration screening determined that the IC50 of Example 1 in the MAO-A assay was 9.8 mM (Ki = 5.7 mM). Low inhibitory effect was seen against MAO-B (17% inhibition at 10 mM).
Example 1 was subject to pharmacological profiling against 39 kinases of the Thermo Fisher SelectScreen kinase profiling panel. At a single concentration of 10 mM, less than 40% inhibition of binding or enzyme activity was observed against all targets in the panel.
Example 1 was screened at single concentrations of 10 mM and 1 mM against 8 cathepsins (B, C, H, K, L, L2, S, Z). The IC50 was calculated for examples against cathepsins B, K, L, S and V.
Figure imgf000051_0001
Figure imgf000051_0002
Examples 1 and 6 have low probability for off-target interactions due to the low affinity for targets in these screening panels. Safety Pharmacology
Examples 1 and 6 were evaluated for effects on the hERG potassium channel, in stably expressed CHO cells at concentrations between 0.01 and 30 mM. Examples 1 and 6 produced maximum inhibition values of 30.2% and 23%, respectively, of the hERG current amplitude at 30 mM indicating little propensity for affecting the QT interval.
Genetic Toxicology
Example 1 was assessed in the bacterial reverse mutation assay (Ames) and in vitro micronucleus assay. All in vitro tests were conducted with and without exogenous metabolic activation using concentrations up to those limited by cytotoxicity or insolubility.
Example 1 did not induce mutations when tested up to 5000 mg/plate with and without metabolic activation in the reverse mutation assay in Salmonella typhimurium strains TA98, TA100, TA1535 and TA97a and the Escherichia Coli strain WP2 uvrA pKM101.
Induction of chromosome damage was assessed using the in vitro micronucleus assay in TK6 cells. Example 1 was negative for induction of micronuclei when incubated for 3 hours in the presence of exogenous metabolic activation followed by 27 hours recovery, and also when incubated for 27 hours in the absence of exogenous metabolic activation followed by 27 hours recovery.
TOM20-ubiquitylation assay
Human cell lines can be challenged with mitochondrial depolarizing agents (ionophores (eg. CCCP, valinomycin), mitochondrial complex inhibitors (oligomycin, antimycin A)) to induce ubiquitylation of TOM20, which is then further promoted in the presence of USP30 inhibitors. TOM20 ubiquitylation is subsequently assessed through western blotting of the cell lysates, with TOM20 ubiquitylation adduct detection possible due to an 8 kDa molecule weight increase for each molecule of ubiquitin added, resulting in laddering of a TOM20 immunoreactive band. TOM20-ubiquitylation levels can be quantified using chemiluminescence densitometry of laddered immunoreactive bands. Further Studies
Definitions:
Physicochemical Properties:
log P: partition coefficient; lipophilicity measurement.
log D: distribution co-efficient; lipophilicity measurement.
TPSA: topological polar surface area.
Turbidimetric solubility: Test compound solution prepared in DMSO diluted into aqueous buffer. Turbidimetry is used as the end-point by measuring absorbance at 620 nm.
FaSSIF: simulated intestinal fluid in fasted state measured at pH 6.5.
Hep Cl mouse: in vitro hepatocyte clearance in mouse cells.
Hep Cl human: in vitro hepatocyte clearance in human cells. Plasma fu,p: The free fraction of a compound in plasma preparation determined by in vitro equilibrium dialysis. It is understood that only unbound (free) compound is capable of engaging with the target. Brain fu,br: The free fraction of a compound in brain homogenate preparation determined by in vitro equilibrium dialysis. It is understood that only unbound (free) compound is capable of engaging with the target.
Clu: in vitro clearance. Clu as defined here is the scaled clearance, in turn calculated from the intrinsic clearance. The intrinsic clearance is the predicted clearance due to hepatic metabolic reactions, determined from incubation of a compound in a hepatocyte preparation. The lower the value in mL/min/kg, the more stable the compound.
Cl in vivo clearance: Pharmacokinetic measurement of the volume of plasma (or any matrix) from which a substance is completely removed per unit time. The lower the value in mL/min/kg, the more stable the compound.
Oral F: Oral Bioavailability.
MDR1-MDCK (Madin-Darby Canine Kidney cell monolayer) (in vitro) flux assay.
Cell TE WB: USP30 endogenous cellular target engagement western blot (WB) assay. Assays the activity of compounds against USP30 in cells using an irreversible activity probe to monitor USP30 activity.
TE ex vivo: USP30 brain tissue target engagement assay.
USP30 endogenous cellular target engagement assay
Hela cells stably overexpressing YFP-Parkin were seeded into 6 well dishes. Once adhered, cells were treated with appropriate concentrations of test compounds or vehicle control for 1 hour at 37°C, 5% CO2. Whole cell lysates were prepared by scraping the cells into cold PBS, centrifuging and lysing in lysis buffer (50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630, 2 mM MgCl2, 10% Glycerol, 5 mM beta-mercaptoethanol, cOmplete mini tablets EDTA free (Roche), PhosStop tablets (Roche)) for 10 mins. The equivalent of 20 µg of protein from the cleared cell lysate was incubated with a final conc of 2.5 µM HA-Ahx-Ahx-Ub-VME probe at room temperature. The reaction was stopped by addition of 5x SDS sample loading buffer and proteins separated by SDS PAGE and western blotting. USP30 was detected using an anti-USP30 Sheep S746D antibody (MRC PPU Reagents and Services) and a rabbit anti sheep secondary IgG (H+L) horseradish peroxidase conjugated (Thermo #31480) and visualised using ECL reagent (GE #RPN2109) on a GE LAS4000 imager. Target engagement was measured by quantitation of the bands corresponding to USP30 and USP30 bound to the Ub-VME probe and expression of this proportion compared to vehicle treated control.
USP30 brain tissue target engagement assay
50 to 100 mg of tissue was homogenised in 3 x volume of lysis buffer (50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630, 2 mM MgCl2, 10% Glycerol, 5 mM beta-mercaptoethanol, cOmplete mini tablets EDTA free (Roche), PhosStop tablets (Roche)) using the Retch Mixer Mill (MM400). The lysates were cleared and protein quantified using the Bradford Protein assay (Pierce). Lysate containing 60 µg protein was incubated with a final conc of 24 µM of HA-Ahx-Ahx-Ub-VME probe for 60 mins at room temperature. The reaction was stopped by addition of 5x SDS sample loading buffer and proteins separated by SDS-PAGE and western blotting. USP30 was detected using an anti-USP30 Sheep S746D antibody (MRC PPU Reagents and Services) and a rabbit anti sheep secondary IgG (H+L) horseradish peroxidase conjugated (Thermo #31480) and visualised using ECL reagent (GE #RPN2109) on a GE LAS4000 imager. Target engagement was measured by quantitation of the bands corresponding to USP30 and USP30 bound to the Ub-VME probe and expression of this proportion compared to vehicle treated control.
In Vitro Cytotoxicity (Cell Tox): Measured in HCT116 human colorectal carcinoma cells using alamarBlue as the assay endpoint. Compound cytotoxicity was measured over a period of 96-hour continual compound exposure.
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000055_0002
Reference Examples A, B, C and D are known DUB inhibitors that have been identified as active as inhibitors of USP30 and share some structural similarity with the compounds of the present invention, possessing the cyanamide structural feature. Example D is disclosed in WO 2016/046530 as having Uchl1 inhibitory activity.
All of Examples 1 to 8 of the present invention are significantly more potent for USP30 than Reference Examples A, B, C and D as measured in the biochemical assay. Example 1 is approximately 7 to 20-fold more potent than Reference Examples A, B and C, and 880-fold more potent than Reference Example D. Example 6 is approximately 8 to 25-fold more potent than Reference Examples A, B and C and 1100-fold more potent than Reference Example D.
Examples 1, 5 and 7 are significantly more selective for USP30 over USP10, USP16, USP21, USP25 and USP28 compared to Reference Examples A and B. Examples 2, 3, 4, 6 and 8 are significantly more selective for USP30 over USP10, USP16, USP21, USP25 and USP28 compared to Reference Examples A, B and C.
Examples 1, 4, 5, 6 and 8 are significantly more selective for USP30 over USP22, USP35 and USP46, compared to Reference Examples A, B and C. Examples 2, 3 and 7 are significantly more selective for USP30 over USP22, USP35 and USP46, compared to Reference Examples A and B.
Examples 1 and 6 are significantly more selective for USP30 over the cathepsins (K, L and S) compared to Reference Examples A, B and C.
Examples 1, 4 and 6 are significantly more potent (³ 3-fold, as measured in the Cell TE WB assay) for USP30 than Reference Example A. Examples 1, 2, 3, 4 and 6 are significantly more potent (> 5-fold as measured in the Cell TE WB assay) for USP30 than Reference Example B. Examples 1, 2, 3, 4 and 6 are significantly more potent (> 200-fold, as measured in the Cell TE WB assay) for USP30 than Reference Example C.
Examples 1 and 6 show significantly improved hepatocyte metabolic stability (as measured in mouse hepatocytes) compared to Reference Examples A, B and C.
Examples 1 and 6 show significantly improved plasma stability (26 to 400-fold and 6 to 97-fold, respectively, as measured in mouse plasma) compared to Reference Examples A, B and C.
Reference Examples A, B and C demonstrate significant cytotoxicity (ratio of Cell Tox EC50 to USP30 IC50) compared to Examples 1, 4, 6 and 8. Reference Examples A and B demonstrate significant cytotoxicity compared to Examples 2, 3, 5 and 7.
The above-identified advantages of the compounds of the invention over the reference examples of the prior art are both significant and unexpected. On their own, and in particular in combination, this superiority makes the compounds of the invention particularly suitable for use in the treatment or prevention of diseases linked to UP30 activity. Preclinical in vivo models
Compounds of the invention may be tested for efficacy in representative in vivo disease models, using standard study procedures from the published literature, including, for example:
(a) Bleomycin-induced lung fibrosis model, which is a leading preclinical in vivo model of Idiopathic Pulmonary Fibrosis. [Kobayashi et al, 2016, J Immunol, 197(2):504-516]
(b) Diet-induced model of NAFLD and glucose homeostasis.
The Diet-induced model of NAFLD and glucose homeostasis allow investigation of therapeutics on both oral glucose tolerance tests and liver steatosis. C57BL/6J mice are allowed ad libitum access to a high fat diet (45%kcal from fat) for at least 16 weeks. Subsequently, Example 1 (50 mg/kg sc; qd) or vehicle were dosed once daily to 10 to 14 mice per group for a period of 43 days. Oral glucose tolerance testing was conducted on day 37, and upon termination, livers were harvested for histopathological examination of NAFLD pathology, including vacuolation, inflammatory cell infiltration and lipid density, which in combination define the NAFLD activity score (NAS). Example 1 treatment resulted in a positive trend towards increased glucose sensitivity compared to vehicle treated animals. Furthermore, Example 1 treated animals also showed a strong positive trend towards reduction in the NAS (Vehicle NAS score 4.9 +/- 0.35 (n=10), Example 1 NAS score 3.5 +/- 0.7 (n=14); p = 0.079 (exact Wilcoxon rank sum test)), indicative of a potential role in the treatment of Liver Steatosis. [Nishida et al, 2013, Lab Invest; Feb;93(2):230-41]
(c) MPTP Model of Parkinson’s Disease, which is a commonly used paradigm for looking at neurodegeneration in the dopaminergic system of the brain which is triggered by chemically-induced mitochondrial dysfunction. [Karuppagouner et al, 2014, Sci Rep.2014 May 2;4:4874]
(d) Ndufs4KO Leigh syndrome model. [Kruse et al, 2008, Cell Metab. Apr;7(4):312-20] (e) Aged mice model: effects on cognitive and motor function. [Kobilo et al, 2014, Learn Mem. Jan 17;21(2):119-26; Creed et al, 2019, Neuroscience. Jun 15;409:169-179]
(f) The unilateral ureteral obstructive kidney disease model (UUO):
UUO causes renal injury characterised by tubular cell injury, interstitial inflammation and fibrosis. It serves as a model of irreversible post-renal acute kidney injury (AKI). Experimental UUO has illustrated the molecular mechanisms of apoptosis, inflammation and fibrosis, all of which are key processes in renal injury, regardless of the primary insult. Consequently, the UUO model provides investigators information beyond obstruction (Chevalier et al, 2009, Kidney Int 75(11): 1145-1152). Example 1 was assessed in the UUO model to determine the ability of the compound to attenuate progressive tubulointerstitial fibrosis and chronic kidney disease (CKD). On day 1 of the study, adult C57BL/6 mice were dosed by oral gavage according to one of the following dosing regimens; Vehicle, 15 mg/kg Example 1 QD or BID. Two hours post dosing on day 1 study mice underwent surgery to ligate the left ureter at two points. Successful UUO surgery was later confirmed by observation of dilation of renal pelvis due to hydronephrosis. The animals were dosed according to their prescribed regimen for 10 days at which point kidneys were harvested, or histopathology assessment and for protein/RNA assessment. Picrosirius Red staining was performed to assess the extent of collagen deposition and IHC was employed to assess relative a-Smooth Muscle Actin (a-SMA) expression.
Results demonstrated that 15 mg/kg Example 1 (p.o.) dosed either QD or BID, statistically reduced collagen deposition as evidenced by reduced picrosirius red staining in ligated kidneys. Assessment of a-SMA staining, revealed that oral dosing of 15 mg/kg Example 1 QD or BID resulted in a non- statistical reduction in a-SMA levels in UUO injured kidneys when compared to vehicle treated controls.
(g) The ischemia-induced acute kidney injury model (AKI):
AKI can be induced by bilateral renal pedical clamping resulting in ischemia reperfusion injury (IRI) resulting in severe loss of renal function tubular damage and inflammation.
Prophylactic administration:
Example 1 was administered to C57BL/6 mice 15 mg/kg (p.o.) and compared to vehicle treatment from Day -1 through to Day +21. On Day 0, mice were anaesthetized, and their left renal pedicle clamped for 45 min, then released to induce IRI. Mice were monitored and urinary kidney injury biomarkers (KIM-1 and NGAL) were measured on Day +1 and +7. On Day +14 and Day +21 kidneys were harvested. Morphology, fibrosis and immune cell infiltration were assessed.
Body weight was similar between groups and remained constant throughout the observation periods. Example 1 appeared to limit urinary kidney injury biomarkers, KIM1 and NGAL on Day +1. There were large interindividual variations and the differences did not reach significance. Macrophage infiltration was significantly reduced on Day +21. Masson trichome stain revealed significantly less tubular atrophy in Example 1 treated animals on Day +14 and Day +21. Fibronectin expression in the cortex was significantly reduced in Example 1 treated mice on Day +14 and +21.
Example 1 demonstrated efficacy in this model of IR-induced CKD. Daily treatment has shown significant benefits towards attenuated tubular atrophy and reduced cortical fibrosis.
Post-injury administration:
On Day 0 (zero) C57BL/6 mice were anaesthetized, and their left renal pedicle clamped for 45 min, then released to induce IRI. Mice were then administered either vehicle or Example 115 mg/kg (p.o.) BID for 21 days, with first treatment starting five hours following IRI surgery (i.e. therapeutics dosing). Mice were monitored and kidneys harvested at Day +21. Kidney sections were quantitatively assessed for relative cellular morphology, fibrosis and macrophage infiltration using blinded histological scoring methods.
Body weight was similar between groups and remained constant throughout the observation periods. Masson trichrome staining revealed significantly less tubular atrophy in Example 1 treated animals on Day +21. Similarly, fibronectin expression and macrophage infiltration in the cortex was also significantly reduced in Example 1 treated mice on Day +21.
Example 1 demonstrated efficacy in this model of IR-induced CKD when dosed therapeutically. Initiating treatment after the establishment of ischemia-reperfusion injury has shown significant benefits towards attenuated tubular atrophy and reduced cortical fibrosis.

Claims

CLAIMS 1. A compound of formula (I)
Figure imgf000060_0001
a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, wherein: R1 is selected from (C1-C4)alkyl, (C1-C4)fluoroalkyl, CH2OCH3 and CH2N(CH3)2;
R2 is selected from hydrogen and methyl; and
R3, R4, R5 and R6 are each independently selected from hydrogen, deuterium and fluorine.
2. A compound according to claim 1, wherein R1 is selected from methyl, CH2F, CHF2, CF3, CH2OCH3 and CH2N(CH3)2.
3. A compound according to claim 2, wherein R1 is methyl.
4. A compound according to claim 2, wherein R1 is CH2OCH3.
5. A compound according to any one of claims 1 to 4, wherein R2 is hydrogen.
6. A compound according to any one of claims 1 to 5, wherein R5 is selected from hydrogen and fluorine; and R3, R4 and R6 are each hydrogen.
7. A compound according to claim 6, wherein R5 is hydrogen.
8. A compound according to claim 1, which is selected from:
N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide;
5-(3-cyano-5-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide; N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)-5-(3-cyanophenyl)-4-methyloxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(fluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(difluoromethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-(methoxymethyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2-carboxamide; N-((3R,5S)-1-cyano-5-((dimethylamino)methyl)pyrrolidin-3-yl)-5-(3-cyanophenyl)oxazole-2- carboxamide; and
5-(3-cyano-4-fluorophenyl)-N-((3R,5R)-1-cyano-5-methylpyrrolidin-3-yl)oxazole-2-carboxamide; a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer.
9. A compound according to any one of claims 1 to 8, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, for use as a medicament.
10. A compound according to any one of claims 1 to 8, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, for use in the treatment or prevention of a condition involving mitochondrial dysfunction, a cancer, or fibrosis.
11. Use of a compound according to any one of claims 1 to 8, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, in the manufacture of a medicament for use in the treatment or prevention of a condition involving mitochondrial dysfunction, a cancer, or fibrosis.
12. A method for the treatment or prevention of a condition involving mitochondrial dysfunction, a cancer, or fibrosis, comprising the step of administering an effective amount of a compound according to any one of claims 1 to 8, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, to a patient in need thereof.
13. A compound, use, or method, according to claims 10 to 12, wherein the condition involving mitochondrial dysfunction is selected from a CNS disorder; neurodegenerative disease; Parkinson’s disease; Alzheimer’s disease; amyotrophic lateral sclerosis; Huntington’s disease; ischemia; stroke; dementia with Lewy bodies; frontotemporal dementia; multiple sclerosis; mitochondrial encephalopathy, lactic acidosis and stroke-like episodes syndrome; materially-inherited diabetes and deafness; Leber's hereditary optic neuropathy; cancer; neuropathy, ataxia, retinitis pigmentosa- maternally inherited Leigh syndrome; Danon disease; diabetes; diabetic nephropathy; metabolic disorders; heart failure; ischemic heart disease leading to myocardial infarction; psychiatric diseases, schizophrenia; multiple sulfatase deficiency; mucolipidosis II; mucolipidosis III; mucolipidosis IV; GMl-gangliosidosis; neuronal ceroid-lipofuscinoses; Alpers disease; Barth syndrome; beta-oxidation defects; carnitine-acyl-carnitine deficiency; carnitine deficiency; creatine deficiency syndromes; co- enzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex III deficiency; complex IV deficiency; complex V deficiency; COX deficiency; chronic progressive external ophthalmoplegia syndrome; CPT I deficiency; CPT II deficiency; glutaric aciduria type II; Kearns- Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency; Leigh disease or syndrome; Leigh Syndrome French Canadian variant; lethal infantile cardiomyopathy; Luft disease; glutaric aciduria type II; medium-chain acyl-CoA dehydrogenase deficiency; myoclonic epilepsy and ragged-red fiber syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome; mitochondrial DNA depletion syndrome; myoneurogastrointestinal disorder and encephalopathy; Pearson syndrome; pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG mutations; medium/short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; and very long-chain acyl-CoA dehydrogenase deficiency; peroxisomal disorders; methylmalonic acidemia; and age- dependent decline in cognitive function and muscle strength.
14. A compound, use, or method, according to claim 13, wherein the neurodegenerative disease is selected from Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, ischemia, stroke, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia; and Parkinson’s disease related to mutations in a-synuclein, parkin, PINK1, GBA, and LRRK2, and autosomal recessive juvenile Parkinson’s disease where parkin is mutated.
15. A compound, use, or method, according to claim 13, wherein the neurodegenerative disease is Leigh syndrome or disease, X-linked Leigh's disease, Leigh Syndrome French Canadian Variant, and/or the symptoms associated with Leigh’s disease.
16. A compound, use, or method, according to claims 10 to 12, wherein the cancer is selected from breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone, liver, soft tissue, cancers of tissue organs, cancers of the blood cells, CML, AML, mantle cell lymphoma, neuroblastoma, melanoma, soft tissue sarcoma, liposarcoma, fibroblastic sarcoma, leiomyosarcoma, hepatocellular carcinoma, osteosarcoma, oesophageal cancer, leukaemia, lymphoma, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing’s sarcoma, nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, non-small cell lung carcinoma, cancer where apoptotic pathways are dysregulated, and cancer where proteins of the BCL- 2 family are mutated, or over or under expressed.
17. A compound, use, or method, according to claims 10 to 12, wherein the fibrosis is selected from fibrosis or a fibrotic disorder associated with the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia.
18. A compound, use, or method, according to claim 17, wherein the fibrosis is selected from fibrosis or a fibrotic disorder associated with major organ diseases, fibroproliferative disorders, and scarring associated with trauma.
19. A compound, use, or method, according to claim 18, wherein the fibrosis is selected from fibrosis or a fibrotic disorder associated with interstitial lung disease, liver cirrhosis, non-alcoholic fatty liver disease, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, kidney disease, acute kidney injury, chronic kidney disease, delayed kidney graft function, heart or vascular disease, diseases of the eye, systemic and local scleroderma, keloids, hypertrophic scars, atherosclerosis, restenosis, Dupuytren’s contracture, surgical complications, chemotherapeutics drug-induced fibrosis, radiation-induced fibrosis, accidental injury and burns, retroperitoneal fibrosis, and peritoneal fibrosis/peritoneal scarring.
20. A compound, use, or method, according to claim 19, wherein the fibrosis associated with interstitial lung disease is selected from sarcoidosis, silicosis, drug reactions, infections, collagen vascular diseases, rheumatoid arthritis, systemic sclerosis, scleroderma, pulmonary fibrosis, idiopathic pulmonary fibrosis, usual interstitial pneumonitis, interstitial lung disease, cryptogenic fibrosing alveolitis, bronchiolitis obliterans, and bronchiectasis.
21. A compound, use, or method, according to claim 19, wherein the kidney disease is acute kidney injury or chronic kidney disease.
22. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 8, a tautomer thereof, or a pharmaceutically acceptable salt of said compound or tautomer, together with one or more pharmaceutically acceptable excipients.
23. A compound, which is selected from formulae (II) and (III):
Figure imgf000063_0001
wherein PG is a protecting group, preferably BOC or CBZ, and R1, R2, R3, R4, R5 and R6 are as defined for the compound of formula (I) in any one of claims 1 to 8, a tautomer thereof, or a salt of said compound or tautomer.
PCT/EP2020/060467 2019-04-16 2020-04-14 Substituted cyanopyrrolidines with activity as usp30 inhibitors WO2020212350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1905371.9 2019-04-16
GBGB1905371.9A GB201905371D0 (en) 2019-04-16 2019-04-16 Novel compounds

Publications (1)

Publication Number Publication Date
WO2020212350A1 true WO2020212350A1 (en) 2020-10-22

Family

ID=66809817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2020/060467 WO2020212350A1 (en) 2019-04-16 2020-04-14 Substituted cyanopyrrolidines with activity as usp30 inhibitors

Country Status (2)

Country Link
GB (1) GB201905371D0 (en)
WO (1) WO2020212350A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021204856A1 (en) 2020-04-08 2021-10-14 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021239863A1 (en) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021249909A1 (en) 2020-06-08 2021-12-16 Mission Therapeutics Limited 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
WO2022084479A1 (en) 2020-10-22 2022-04-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
US11535618B2 (en) 2018-10-05 2022-12-27 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
US12049466B2 (en) 2018-05-17 2024-07-30 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2006067165A2 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080300268A1 (en) 2007-06-04 2008-12-04 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009026197A1 (en) 2007-08-20 2009-02-26 Glaxo Group Limited Novel cathepsin c inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129365A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2012170290A1 (en) 2011-06-04 2012-12-13 Jb Therapeutics, Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
WO2013030218A1 (en) 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7
WO2015017502A1 (en) 2013-07-31 2015-02-05 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
WO2015183987A1 (en) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
WO2017093718A1 (en) 2015-11-30 2017-06-08 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as inhibitors of usp30.
WO2017103614A1 (en) 2015-12-17 2017-06-22 Mission Therapeutics Limited Novel Compounds
WO2017109488A1 (en) 2015-12-23 2017-06-29 Mission Therapeutics Limited Cyanopyrrolidine dervivatives as inhibitors for dubs
WO2017141036A1 (en) 2016-02-18 2017-08-24 Mission Therapeutics Limited Novel compounds
WO2017149313A1 (en) 2016-03-04 2017-09-08 Mission Therapeutics Limited Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
WO2017158381A1 (en) 2016-03-18 2017-09-21 Mission Therapeutics Limited 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer
WO2017158388A1 (en) 2016-03-18 2017-09-21 Mission Therapeutics Limited 2-cyanoisoindoline derivatives for treating cancer
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
WO2018060742A1 (en) 2016-09-30 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
WO2018060691A1 (en) 2016-09-29 2018-04-05 Mission Therapeutics Limited Cyano-subtituted heterocycles with activity as inhibitors of usp30
WO2018060689A1 (en) 2016-09-27 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
WO2018065768A1 (en) 2016-10-05 2018-04-12 Mission Therapeutics Limited Cyano-substituted heterocycles with activity as inhibitors of usp30
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors
WO2018220355A1 (en) 2017-05-31 2018-12-06 Mission Therapeutics Limited Sulfonamide-substituted cyanopyrrolidines with activity as dub inhibitors
WO2018234755A1 (en) 2017-06-19 2018-12-27 Edwards Limited Twin-shaft pumps
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
WO2019171042A1 (en) 2018-03-06 2019-09-12 Mission Therapeutics Limited Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment
WO2019222468A1 (en) 2018-05-17 2019-11-21 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106864A (en) 1995-09-15 2000-08-22 Pfizer Inc. Pharmaceutical formulations containing darifenacin
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2006067165A2 (en) 2004-12-24 2006-06-29 Boehringer Ingelheim International Gmbh Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
US20080300268A1 (en) 2007-06-04 2008-12-04 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2009026197A1 (en) 2007-08-20 2009-02-26 Glaxo Group Limited Novel cathepsin c inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129365A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2012170290A1 (en) 2011-06-04 2012-12-13 Jb Therapeutics, Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
WO2013030218A1 (en) 2011-09-02 2013-03-07 Hybrigenics Sa Selective and reversible inhibitors of ubiquitin specific protease 7
WO2015017502A1 (en) 2013-07-31 2015-02-05 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
WO2015179190A1 (en) 2014-05-19 2015-11-26 Northeastern University N-acylethanolamine hydrolyzing acid amidase (naaa) inhibitors and their use thereof
WO2015183987A1 (en) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016046530A1 (en) 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
WO2017093718A1 (en) 2015-11-30 2017-06-08 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as inhibitors of usp30.
WO2017103614A1 (en) 2015-12-17 2017-06-22 Mission Therapeutics Limited Novel Compounds
WO2017109488A1 (en) 2015-12-23 2017-06-29 Mission Therapeutics Limited Cyanopyrrolidine dervivatives as inhibitors for dubs
WO2017141036A1 (en) 2016-02-18 2017-08-24 Mission Therapeutics Limited Novel compounds
WO2017149313A1 (en) 2016-03-04 2017-09-08 Mission Therapeutics Limited Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
WO2017158381A1 (en) 2016-03-18 2017-09-21 Mission Therapeutics Limited 4,6 dihydropyrrolo [3,4-c] pyrazole-5 (1h)-carbonitrile derivates for trating cancer
WO2017158388A1 (en) 2016-03-18 2017-09-21 Mission Therapeutics Limited 2-cyanoisoindoline derivatives for treating cancer
WO2017163078A1 (en) 2016-03-24 2017-09-28 Mission Therapeutics Limited 1-cyano-pyrrolidine derivatives as dbu inhibitors
WO2018060689A1 (en) 2016-09-27 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
WO2018060691A1 (en) 2016-09-29 2018-04-05 Mission Therapeutics Limited Cyano-subtituted heterocycles with activity as inhibitors of usp30
WO2018060742A1 (en) 2016-09-30 2018-04-05 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of usp30
WO2018065768A1 (en) 2016-10-05 2018-04-12 Mission Therapeutics Limited Cyano-substituted heterocycles with activity as inhibitors of usp30
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors
WO2018220355A1 (en) 2017-05-31 2018-12-06 Mission Therapeutics Limited Sulfonamide-substituted cyanopyrrolidines with activity as dub inhibitors
WO2018234755A1 (en) 2017-06-19 2018-12-27 Edwards Limited Twin-shaft pumps
WO2019071073A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
WO2019171042A1 (en) 2018-03-06 2019-09-12 Mission Therapeutics Limited Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment
WO2019222468A1 (en) 2018-05-17 2019-11-21 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
ARAYA ET AL., AUTOPHAGY, vol. 15, no. 3, 2019, pages 510 - 526
BEDFORD ET AL., NATURE REV, vol. 10, 2011, pages 29 - 46
BINGOL ET AL., NATURE, vol. 510, 2015, pages 370 - 5
CHAWLA ET AL., NAT REV NEPHROL, vol. 13, no. 4, 2017, pages 241 - 257
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1207853-53-9
CHEVALIER ET AL., KIDNEY INT, vol. 75, no. 11, 2009, pages 1145 - 1152
CONNOR ET AL., PLOS GENET, vol. 13, no. 3, 2017, pages el006620
CREED ET AL., NEUROSCIENCE, vol. 409, 15 June 2019 (2019-06-15), pages 169 - 179
CUNNINGHAM ET AL., NAT CELL BIOL, vol. 17, no. 2, 2015, pages 160 - 169
E. L. ELIELS. H. WILEN: "Stereochemistry of Organic Compounds", 1994, WILEY
EIRIN ET AL., HANDB EXP PHARMACOL, vol. 240, 2017, pages 229 - 250
EMMA ET AL., NAT REV NEPHROL, vol. 12, no. 5, 2016, pages 267 - 280
FALGUEYRET ET AL., J.MED.CHEM., vol. 44, 2001, pages 94 - 104
GERSCH ET AL., NAT STRUCT MOL BIOL, vol. 24, no. 11, 2017, pages 920 - 930
H BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
HALEBLIAN, J. PHARM SCI, vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
JACOUPY ET AL., SCI REP, vol. 9, no. 1, 2019, pages 11829
KARUPPAGOUNER ET AL., SCI REP., vol. 4, 2 May 2014 (2014-05-02), pages 4874
KAWAKAMI ET AL., J AM SOC NEPHROL, vol. 26, no. 5, 2015, pages 1040 - 1052
KOBAYASHI ET AL., J IMMUNOL, vol. 197, no. 2, 2016, pages 504 - 516
KOBILO ET AL., LEARN MEM., vol. 21, no. 2, 17 January 2014 (2014-01-17), pages 119 - 26
KRUSE ET AL., CELL METAB., vol. 7, no. 4, April 2008 (2008-04-01), pages 312 - 20
KURITA ET AL., RESPIRATORY RESEARCH, vol. 18, 2017, pages 114
LARSON-CASEY ET AL., IMMUNITY, vol. 44, 2016, pages 582 - 596
LIANGCHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986
MCWILLIAMS ET AL., CELL METAB, vol. 27, no. 2, 2018, pages 439 - 449 e435
MEHTA ET AL., LANCET, vol. 385, no. 9987, 2015, pages 2616 - 2643
NAKAMURA ET AL., MOL BIOL, vol. 19, 2008, pages 1903 - 11
NISHIDA ET AL., LAB INVEST, vol. 93, no. 2, February 2013 (2013-02-01), pages 230 - 41
PHU ET AL., MOLECULAR CELL, vol. 77, 2020, pages 1107 - 1123
RICCIO ET AL., J CELL BIOL, vol. 218, no. 3, 2019, pages 798 - 807
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH
TANG ET AL., AUTOPHAGY, vol. 14, no. 5, 2018, pages 880 - 897
TANG ET AL., KIDNEY DISEASES, vol. 1, 2015, pages 71 - 79
VERMA ET AL., PHARMACEUTICAL TECHNOLOGY ON-LINE, vol. 25, no. 2, 2001, pages 1 - 14
WANG ET AL., CELL DEATH DIS, vol. 9, no. 11, 2018, pages 1113
WILLIAMS ET AL., AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 309, 2015, pages G324 - G340
WILLIAMS ET AL., BIOMOLECULES, vol. 5, 2015, pages 2619 - 2642
WILLIAMS ET AL., PHARMACOL RES., vol. 102, December 2015 (2015-12-01), pages 264 - 269
WYNN ET AL., NAT REV IMMUNOL., vol. 4, no. 8, August 2004 (2004-08-01), pages 583 - 594

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12049466B2 (en) 2018-05-17 2024-07-30 Forma Therapeutics, Inc. Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US11535618B2 (en) 2018-10-05 2022-12-27 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
US11814386B2 (en) 2018-10-05 2023-11-14 Forma Therapeutics, Inc. Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
WO2021204856A1 (en) 2020-04-08 2021-10-14 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021239863A1 (en) 2020-05-28 2021-12-02 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
WO2021245186A1 (en) 2020-06-04 2021-12-09 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021249909A1 (en) 2020-06-08 2021-12-16 Mission Therapeutics Limited 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
WO2022084479A1 (en) 2020-10-22 2022-04-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
WO2023099561A1 (en) 2021-12-01 2023-06-08 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Also Published As

Publication number Publication date
GB201905371D0 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
EP4025573B9 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
WO2020212350A1 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
WO2020212351A1 (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors
EP4157834B1 (en) N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
EP4132925A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
EP4161929B1 (en) 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
EP4161920A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
WO2022084479A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors
EP4441044A1 (en) Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
HK40068349A (en) Substituted cyanopyrrolidines with activity as usp30 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20719176

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20719176

Country of ref document: EP

Kind code of ref document: A1